# 84.3123 Male

**Page range:** 518â€“647

```text
84.3123
Male
UNITED STATES OF
AMERICA
Non-Interventional
Study/Program
Non-healthcare
professional
Cellulitis
NR
10
(1) PRALSETINIB (S)

(2) TAMSULOSIN (C)

(3) RIVAROXABAN (C)

(4) SPIRONOLACTONE
(C)

(5) FUROSEMIDE (C)

(6) DEXAMETHASONE (C)

(7) IPRATROPIUM
BROMIDE (C)

(8) PRAVASTATIN (C)

(9) METOPROLOL (C)
NR
Unknown
N/A
Recovered/Resolved

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to Onset (in
days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome

(10) AMOXICILLIN (C)
3195341
55
Female
FRANCE
Spontaneous
Non-healthcare
professional
Pneumonia
cytomegaloviral

Pneumocystis jirovecii
pneumonia
NR

NR
150

150
(1) PRALSETINIB (S)

(2) PREDNISONE (S)

(3) ZOLPIDEM TARTRATE
(C)

(4) CALCIUM
CARBONATE\COLECALCI
FEROL (C)

(5) GABAPENTIN (C)

(6) OXAZEPAM (C)

(7) OMEPRAZOLE (C)

(8) LEVETIRACETAM (C)
Dose interrupted

Dose interrupted


Positive

Positive
N/A

N/A
Recovering/Resolving

Recovering/Resolving
3205949
60
Female
NETHERLANDS
Non-Interventional
Study/Program
Healthcare Professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)

(2)
AMOXICILLIN\CLAVULAN
ATE POTASSIUM (T)
NR
Unkown
N/A
Not Reported
3219847
77
Male
UNITED STATES OF
AMERICA
Spontaneous
Hepatitis B

Pneumonia
NR

NR
NR

NR
(1) PRALSETINIB (S)

(2) TENOFOVIR
ALAFENAMIDE
FUMARATE (S)
Dose interrupted

NR
Unkown

Unknown
Unknown

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to Onset (in
days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Non-healthcare
professional

Unknown
Not Reported

Not reported
3255319
81
Male
CHINA
Literature Spontaneous
Non-healthcare
professional
Pneumonia cryptococcal

Lung abscess
NR

NR
144

234
(1) PRALSETINIB (S)

(2) ALECTINIB (S)

(3) FLUCONAZOLE (T)

(4) VORICONAZOLE (T)

(5) BIAPENEM (T)

(6) CISPLATIN (T)

(7) BEVACIZUMAB (T)

(8) MITOMYCIN (T)
NR

NR


Unkown

Unknown
N/A

N/A
Recovering/Resolving

Recovering/Resolving
3337315
Not reported
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare
professional
Pneumonia
NR
121
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Recovered/Resolved
3349170
61
Male
CHINA
Spontaneous
Infection
NR
NR
(1) PRALSETINIB (S)
Dose interrupted

Dose interrupted
Positive
N/A
Recovered/Resolved

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to Onset (in
days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Non-healthcare
professional
3430100
44
Male
CHINA
Literature Spontaneous
Non-healthcare
professional
Pulmonary tuberculosis

Tuberculous pleurisy
NR

NR
212

NR
(1) PRALSETINIB (S)

(2) ETHAMBUTOL
DIHYDROCHLORIDE (T)

(3) PYRAZINAMIDE (T)

(4) MOXIFLOXACIN (T)
Dose interrupted

Dose interrupted


Positive

Positive
Unknown

Unknown


Recovering/Resolving

Recovering/Resolving
3467781
Not reported
Male
IRELAND
Spontaneous
Healthcare Professional
Fungal foot infection
NR
NR
(1) PRALSETINIB (S)
Dose interrupted
Unknown
N/A
Not Reported
3517666
Not reported
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare
professional
Liver abscess
NR
2
(1) PRALSETINIB (S)

(2) NIFEDIPINE (C)

(3) INSULIN NOS (C)
Dose interrupted
Positive
Unknown
Recovered/Resolved

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to Onset (in
days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
3528428
43
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare
professional
Pulmonary tuberculosis
NR
173
(1) PRALSETINIB (S)

(2) VORICONAZOLE (T)
Dose not changed
N/A
N/A
Recovering/Resolving
10000040960
Not reported
Male
CHINA
Spontaneous
Non-healthcare
professional
Fungal infection

Bacterial infection
NR

NR
37

7
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Not Reported

Not Reported
3065813
64
Female
ITALY
Non-Interventional
Study/Program
Healthcare Professional
Sepsis

Abdominal abscess


Grade 5

NR
NR

NR
(1) PRALSETINIB (S)

(2) LEVOTHYROXINE
SODIUM (S)

(3) BISOPROLOL (S)

(4) FUROSEMIDE (S)

(5)
METHYLPREDNISOLONE
(S)

(6) APIXABAN (S)

(7) PANTOPRAZOLE
SODIUM
SESQUIHYDRATE (C)
N/A

N/A
N/A

N/A
N/A

N/A
Fatal

Not Reported


Category C (N=223)
AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
2727399
67
Female
UNITED STATES OF
AMERICA
Spontaneous
Non-healthcare professional
Cellulitis
NR
12
(1) PRALSETINIB (S)
Dose interrupted
Pos
NA
Resolved
2769291
67
Female
UNITED STATES OF
AMERICA
Spontaneous
Non-healthcare professional
Pneumonia


NR
84
(1) PRALSETINIB (S)
Drug withdrawn
Unknown
N/A
 Not Recovered/Not
Resolved/Ongoing
2775653
72
Male
UNITED STATES OF
AMERICA
Spontaneous
Non-healthcare professional
Infection susceptibility
increased
NR
85
(1) PRALSETINIB (S)
Dose not changed
NA
NA
Not Resolved
2776893
37
Female
UNITED STATES OF
AMERICA
Spontaneous
Non-healthcare professional
Hepatic infection
NR
16
(1) PRALSETINIB (S)
Dose interrupted
Neg
NA
Not Resolved
2783639
Not reported
Male
UNITED STATES OF
AMERICA
Spontaneous
Non-healthcare professional
Cellulitis
NR
NR
(1) PRALSETINIB (S)
Dose interrupted
Unk
NA
Unknown
2785349
85
Male
UNITED STATES OF
AMERICA
Enterococcal infection

Urinary tract infection
NR

NR
26

26
(1) PRALSETINIB (S)
Dose interrupted

Dose interrupted
Negative

Negative

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Spontaneous
Non-healthcare professional
N/A

N/A
Not Recovered/Not
Resolved/Ongoing

Not Recovered/Not
Resolved/Ongoing
2796604
36
Female
UNITED STATES OF
AMERICA
Spontaneous
Non-healthcare professional
Liver abscess
NR
33
(1) PRALSETINIB (S)
Dose not changed
NA
NA
Not Resolved
2802310
43
Male
UNITED STATES OF
AMERICA
Spontaneous
Non-healthcare professional
Pneumonia
NR
0
(1) PRALSETINIB (S)
Dose interrupted
Neg
NA
Not Resolved
2802446
43
Male
UNITED STATES OF
AMERICA
Spontaneous
Non-healthcare professional
Pneumonia
NR
24
(1) PRALSETINIB (S)
Dose interrupted
Unk
NA
Unknown
2802504
Not reported
Male
UNITED STATES OF
AMERICA
Spontaneous
Non-healthcare professional
Prostate infection
NR
NR
(1) PRALSETINIB (S)

(2) LEVOFLOXACIN (T)
NR
Unknown
N/A
Not Resolved
2807851
43
Male
UNITED STATES OF
AMERICA
Pneumonia
NR
53
(1) PRALSETINIB (S)
Dose interrupted
Unk
NA
Unknown

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Spontaneous
Healthcare Professional
2812730
43
Female
UNITED STATES OF
AMERICA
Spontaneous
Non-healthcare professional
Infection
NR
0
(1) PRALSETINIB (S)
Dose not changed
NA
NA
Not Recovered/Not
Resolved/Ongoing
2818321
84
Male
UNITED STATES OF
AMERICA
Spontaneous
Non-healthcare professional
Urosepsis

Urinary tract infection

Sepsis
NR

NR

NR
98

98

98
(1) PRALSETINIB (S)
Drug withdrawn

Dose not changed

Dose not changed
Negative

NA

NA
NA

NA

NA
Not Recovered/Not
Resolved/Ongoing

Not Recovered/Not
Resolved/Ongoing

Recovered/Resolved
2831537
67
Male
UNITED STATES OF
AMERICA
Spontaneous
Non-healthcare professional
Pneumonia
NR
181
(1) PRALSETINIB (S)
Dose not changed
NA
NA
Resolved

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
2832829
46
Female
UNITED STATES OF
AMERICA
Spontaneous
Non-healthcare professional
COVID-19

Pneumonia
NR

NR
25

25
(1) PRALSETINIB (S)

(2) CYCLOBENZAPRINE
HYDROCHLORIDE (T)
Dose not changed

Dose not changed
NA

NA
NA

NA
Unknown

Unknown
2842714
Not reported
Male
UNITED STATES OF
AMERICA
Spontaneous
Non-healthcare professional
Staphylococcal infection
NR
NR
(1) PRALSETINIB (S)

(2) TAMSULOSIN (C)

(3) METOPROLOL (C)

(4) AMLODIPINE (C)

(5) FAMOTIDINE (C)

(6) FISH OIL (C)
Dose not changed
NA
NA
Not Reported
2844803
61
Herpes zoster
NR
177
(1) PRALSETINIB (S)
Dose interrupted
Neg

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Female
UNITED STATES OF
AMERICA
Spontaneous
Non-healthcare professional
NA
Not Resolved

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
2849379
Not reported
Female
UNITED STATES OF
AMERICA
Spontaneous
Non-healthcare professional
Infection
NR
NR
(1) PRALSETINIB (S)

(2) AMLODIPINE (C)

(3) FUROSEMIDE (C)

(4) LEVOTHYROXINE (C)

(5) LISINOPRIL (C)

(6) MAGNESIUM (C)

(7) METOPROLOL (C)

(8) MIDODRINE (C)

(9) DOCOSAHEXAENOIC
ACID\EICOSAPENTAENOIC ACID (C)

(10) OXYCODONE (C)

(11) PANTOPRAZOLE (C)

(12) MACROGOL 3350 (C)

(13) SENNA SPP. (C)

(14) WARFARIN (C)
Dose not changed
NA
NA
Not reported

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
2866603
Not reported
Female
UNITED STATES OF
AMERICA
Spontaneous
Healthcare Professional
Oral candidiasis
NR
4
(1) PRALSETINIB (S)
Dose interrupted
Pos
NA
Resolved
2881497
48
Male
CHINA
Spontaneous
Healthcare Professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)
Dose not changed
NA
NA
Unknown
2882115
85
Female
UNITED STATES OF
AMERICA
Non-Interventional
Study/Program
Non-healthcare professional
Urinary tract infection
bacterial
NR
NR
(1) PRALSETINIB (S)

(2)
SULFAMETHOXAZOLE\TRIMETHOPRIM
(T)
NR
Unknown
N/A
Unknown
2888383
70
Male
CHINA
Spontaneous
Healthcare Professional
Sepsis
NR
24
(1) PRALSETINIB (S)
Drug withdrawn
Positive
NA
 Recovered/Resolved
2892868
79
Male
INDIA
Non-Interventional
Study/Program
Non-healthcare professional
Urinary tract infection
NR
43
(1) PRALSETINIB (S)
Drug withdrawn
NA
NA
NR
2902745
73
Male
CHINA
Pneumonia
NR
124
(1) PRALSETINIB (S)
Drug withdrawn
NA
NA
Unknown

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Spontaneous
Non-healthcare professional
2904489
58
Female
CHINA
Spontaneous
Non-healthcare professional
Pneumonia
NR
60
(1) PRALSETINIB (S)
Drug withdrawn
Unk
NA
Unknown
2908467
75
Female
CHINA
Spontaneous
Non-healthcare professional
Nasopharyngitis
NR
64
(1) PRALSETINIB (S)
Dose interrupted
NA
NA
 Unknown
2911785
Not reported
Female
PERU
Non-Interventional
Study/Program
Healthcare Professional
Cellulitis
NR
NR
(1) PRALSETINIB (S)

(2) GABAPENTIN (C)

(3) VITAMIN B COMPLEX (C)
modification of dose
NA
NA
NR
2918762
70
Male
CHINA
Non-Interventional
Study/Program
Healthcare Professional
Sepsis
NR
24
(1) PRALSETINIB (S)

(2) TISLELIZUMAB (C)
Drug withdrawn
Positive
NA
 Recovered/Resolved
2919095
52
Female
Pneumonia
NR
150
(1) PRALSETINIB (S)
Drug withdrawn
Unk

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
NA
Unknown
2919955
46
Female
CHINA
Spontaneous
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)
NR
Unknown
N/A
Unknown
2920549
59
Female
CHINA
Spontaneous
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)
Dose interrupted
Unk
NA
Unknown
2920757
Not reported
Not reported
UNITED KINGDOM
Non-Interventional
Study/Program
Non-healthcare professional
Bacterial sepsis
NR
NR
(1) PRALSETINIB (S)
NR
Unknown
N/A
Not Reported
2929798
Not reported
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Nasopharyngitis
NR
250
(1) PRALSETINIB (S)
Dose not changed
NA
NA
Unknown

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
2941881
59
Female
CHINA
Spontaneous
Non-healthcare professional
Nasopharyngitis

Infection
NR

NR
NR

NR
(1) PRALSETINIB (S)

(2) FLUTICASONE
PROPIONATE\SALMETEROL
XINAFOATE (T)
Dose interrupted

Dose interrupted
Positive

Positive
NA

NA
Recovering/Resolving

Recovering/Resolving
2946575
57
Female
KOREA, REPUBLIC OF
Non-Interventional
Study/Program
Non-healthcare professional
Pyelonephritis

Lymph node tuberculosis
NR

NR
136

51
(1) PRALSETINIB (S)

(2) ISONIAZID (C)

(3) ETHAMBUTOL (C)
NR

NR
Unknown

Unknown
N/A

N/A
Resolved

Resolved
2951571
Not reported
Not reported
CHINA
Spontaneous
Non-healthcare professional
Pneumocystis jirovecii
pneumonia
NR
31
(1) PRALSETINIB (S)

(2) AMOXICILLIN (T)
Dose reduced
Unknown
Unknown
Unknown
2954830
Not reported
Male
Pneumonia
NR
24
(1) PRALSETINIB (S)
Dose not changed
NA

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
CHINA
Spontaneous
Non-healthcare professional
NA
Not Resolved
2955349
79
Female
UNITED STATES OF
AMERICA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)
NR
Unknown
N/A
Resolving
2959905
60
Female
CHINA
Spontaneous
Non-healthcare professional
Pneumocystis jirovecii
pneumonia
NR
82
(1) PRALSETINIB (S)
Drug withdrawn
Negative
NA
Not Recovered/Not
Resolved/Ongoing
2963526
56
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
29
(1) PRALSETINIB (S)
Dose not changed
NA
NA
Unknown

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
2963946
59
Female
NETHERLANDS
Non-Interventional
Study/Program
Non-healthcare professional
Urinary tract infection
NR
84
(1) PRALSETINIB (S)

(2)
COLOSTRUM\HYETELLOSE\LACTOPER
OXIDASE\MALTOSE\SODIUM
FLUOROPHOSPHATE\SORBITOL\XYLIT
OL (C)

(3) CAFFEINE\PARACETAMOL (C)

(4) ONDANSETRON (C)

(5)
SULFAMETHOXAZOLE\TRIMETHOPRIM
(C)

(6) PARACETAMOL (C)
N/A
N/A
N/A
 Recovering/Resolving

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
2968652
68
Female
PERU
Non-Interventional
Study/Program
Healthcare Professional
Pulmonary sepsis

Pneumonia
NR

NR
(1) PRALSETINIB (S)
NR

NR
Unknown

Unknown
N/A

N/A
Not Recovered/Not
Resolved/Ongoing

Not Reported
2974208
75
Female
ITALY
Spontaneous
Non-healthcare professional
Listeriosis

Bronchopulmonary
aspergillosis

Enterococcal sepsis

Pneumonia cytomegaloviral

Escherichia sepsis
NR

NR

NR

NR

NR
18

18

18

18

18
(1) PRALSETINIB (S)
Drug withdrawn
Neg
NA
Not Resolved

Not Resolved

Not Resolved

Not Resolved

Not Resolved

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
2974550
65
Female
ITALY
Non-Interventional
Study/Program
Healthcare Professional
Device related sepsis
NR
NR
(1) PRALSETINIB (S)

(2) PANTOPRAZOLE (C)

(3) ATENOLOL (C)

(4) OXYCODONE (C)

(5) DULOXETINE (C)

(6) AMLODIPINE (C)

(7) NADROPARIN CALCIUM (C)

(8) LEVOSULPIRIDE (C)

(9) CYANOCOBALAMIN (C)

(10) THIAMAZOLE (C)
Drug interrupted
NA
NA
Unknown

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
2974677
Not reported
Not reported
CHINA
Spontaneous
Non-healthcare professional
Pneumonia
NR
14
(1) PRALSETINIB (S)
Dose interrupted
NEg
NA
Not Resolved
2974851
65
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
182
(1) PRALSETINIB (S)
NR
Unkown
N/A
Not Recovered/Not
Resolved/Ongoing
2977940
78
Female
CHINA
Spontaneous
Non-healthcare professional
Viral infection
NR
34
(1) PRALSETINIB (S)
Dose not changed
NA
NA
Resolving
2982419
72
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
12
(1) PRALSETINIB (S)
Drug withdrawn
Positive
NA
 Recovering/Resolving
2982421
45
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
61
(1) PRALSETINIB (S)
Dose interrupted
Pos
Neg
Resolving
2987198
50
Male
KOREA, REPUBLIC OF
Non-Interventional
Study/Program
Non-healthcare professional
Chronic sinusitis
NR
202
(1) PRALSETINIB (S)
NR
Unkown
N/A
Recovered/Resolved
2988507
34
Female
CHINA
Pneumonia
NR
249
(1) PRALSETINIB (S)
NR
Unknown
N/A
Not Resolved

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Non-Interventional
Study/Program
Non-healthcare professional
2995238
54
Female
KOREA, REPUBLIC OF
Non-Interventional
Study/Program
Healthcare Professional
Pyelonephritis acute
NR
691
(1) PRALSETINIB (S)
NR
Unknown
N/A
Recovered/Resolved
2998059
82
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
330
(1) PRALSETINIB (S)
Dose not changed
NA
NA
Resolving
2998101
Not reported
Male
ISRAEL
Spontaneous
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)
NR
Unknown
N/A
Not Reported
2998731
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Lymph node tuberculosis
NR
NR
(1) PRALSETINIB (S)
NR
Unknown
N/A
Unknown
3006308
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
137
(1) PRALSETINIB (S)
Dose interrupted
Pos
NA
Resolving
3008928
59
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
75
(1) PRALSETINIB (S)
Drug interrupted
Negative
NA
Not Recovered/Not
Resolved/Ongoing

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
3009926
77
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)
Dose not changed
NA
NA
Not Resolved
3028355
66
Male
NEW ZEALAND
Spontaneous
Healthcare Professional
Lower respiratory tract
infection

Herpes zoster
NR

NR
46

46
(1) PRALSETINIB (S)

(2) AMOXICILLIN\CLAVULANATE
POTASSIUM (T)

(3) VALACICLOVIR (T)
NR

NR
Unknown
N/A
Resolved

Resolved
3033200
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
29
(1) PRALSETINIB (S)
Dose interrupted
Neg
NA
Not Resolved
3038753
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Appendicitis

Tuberculosis
NR

NR
122

168
(1) PRALSETINIB (S)
NR

NR
Unknown

Unknown
N/A

N/A
Not Recovered/Not

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Resolved/Ongoing

Not Recovered/Not
Resolved/Ongoing
3041704
Not reported
Not reported
SPAIN
Non-Interventional
Study/Program
Non-healthcare professional
COVID-19 pneumonia
NR
NR
(1) PRALSETINIB (S)
NR
Unknown
N/A
Not Reported
3042661
Not reported
Male
CANADA
Non-Interventional
Study/Program
Healthcare Professional
Pneumonia legionella
NR
NR
(1) PRALSETINIB (S)
NR
Unknown
N/A
Not Reported
3043347
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
52
(1) PRALSETINIB (S)
Dose interrupted
Neg
NA
Not Resolved
3048742
Not reported
Not reported
INDIA
Non-Interventional
Study/Program
Healthcare Professional
Tuberculosis
NR
NR
(1) PRALSETINIB (S)
NR
Unkown
N/A
Not Reported
3053470
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
63
(1) PRALSETINIB (S)
Drug withdrawn
Positive
NA
 Recovering/Resolving
3059596
Not reported
Not reported
CHINA
Non-Interventional
Pneumonia
NR
93
(1) PRALSETINIB (S)
Drug withdrawn
Positive
NA
 Recovering/Resolving

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Study/Program
Non-healthcare professional
3060681
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Herpes zoster
NR
34
(1) PRALSETINIB (S)
Dose not changed
NA
NA
Not Recovered/Not
Resolved/Ongoing
3062048
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
42
(1) PRALSETINIB (S)
Dose not changed
NA
NA
Not Recovered/Not
Resolved/Ongoing
3063921
69
Male
SPAIN
Non-Interventional
Study/Program
Healthcare Professional
Spinal cord abscess
NR
NR
(1) PRALSETINIB (S)
Drug interrupted
NA
NA
 Recovering/Resolving
3064070
42
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
120
(1) PRALSETINIB (S)

(2) GEFITINIB (C)
Dose not changed
NA
NA
Not Recovered/Not
Resolved/Ongoing
3076615
44
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia bacterial
NR
0
(1) PRALSETINIB (S)
Dose not changed
NA
NA
Unknown
3081192
Not reported
Not reported
CHINA
Pneumonia
NR
276
(1) PRALSETINIB (S)
Dose not changed
NA
NA
Recovering/Resolving

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Non-Interventional
Study/Program
Non-healthcare professional
3082744
Not reported
Male
UNITED STATES OF
AMERICA
Spontaneous
Non-healthcare professional
Arthritis bacterial
NR
NR
(1) PRALSETINIB (S)
Drug withdrawn
NA
NA
Unknown
3083018
56
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
270
(1) PRALSETINIB (S)
Drug withdrawn
Negative
NA
 Not Recovered/Not
Resolved/Ongoing
3087488
64
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
213
(1) PRALSETINIB (S)
Dose not changed
NA
NA
Recovering/Resolving
3092325
65
Male
UNITED STATES OF
AMERICA
Non-Interventional
Study/Program
Healthcare Professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)
NR
Unkown
N/A
Not Reported
3093310
67
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia


NR
93
(1) PRALSETINIB (S)
Dose not changed
NA
NA
Recovering/Resolving
3094935
56
Female
CHINA
Non-Interventional
Pneumonia
NR
55
(1) PRALSETINIB (S)
N/A
N/A
N/A
Not Recovered/Not
Resolved/Ongoing

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Study/Program
Non-healthcare professional
3096494
62
Male
ITALY
Non-Interventional
Study/Program
Healthcare Professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)
Drug withdrawn
NA
NA
NR
3097721
67
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
93
(1) PRALSETINIB (S)
Drug withdrawn
NA
NA
 Recovering/Resolving
3100285
66
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)

(2) OSIMERTINIB (C)
NR
Unknown
N/A
Recovering/Resolving
3100527
42
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
206
(1) PRALSETINIB (S)
Dose not changed
NA
NA
Not Recovered/Not
Resolved/Ongoing
3105028
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
69
(1) PRALSETINIB (S)
Dose not changed
NA
NA
Recovering/Resolving
3116576
Not reported
Not reported
Pneumonia
NR
328
(1) PRALSETINIB (S)
Dose not changed
NA

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
NA
Recovering/Resolving
3118408
55
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
51
(1) PRALSETINIB (S)
Dose not changed
NA
NA
Not Recovered/Not
Resolved/Ongoing
3120942
57
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia


NR
69
(1) PRALSETINIB (S)
NR
Unkown
N/A
Not Recovered/Not
Resolved/Ongoing
3121806
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)
NR
Unkown
N/A
Unknown
3122985
63
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
151
(1) PRALSETINIB (S)
Dose reduced
Negative
NA
Not Recovered/Not
Resolved/Ongoing
3126681
34
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
71
(1) PRALSETINIB (S)
Dose reduced
Negative
NA
 Not Recovered/Not
Resolved/Ongoing
3126688
71
Female
CHINA
Non-Interventional
Abdominal infection

Pneumonia
NR
118

118
(1) PRALSETINIB (S)
NR

NR


AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Study/Program
Non-healthcare professional

NR
Unkown

Unknown
N/A

N/A
Not Recovered/Not
Resolved/Ongoing

Not Recovered/Not
Resolved/Ongoing
3127587
50
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Paronychia

Pneumonia
NR

NR
12

89
(1) PRALSETINIB (S)
Dose not changed

Dose not changed
N/A

N/A

N/A


N/A

N/A

N/A


Not Recovered/Not
Resolved/Ongoing

Not Recovered/Not
Resolved/Ongoing
3127600
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
87
(1) PRALSETINIB (S)
Drug withdrawn
Positive
NA
 Recovering/Resolving
3132376
42
Male
CHINA
Pneumonia
NR
42
(1) PRALSETINIB (S)
Drug withdrawn
Neg
NA
Not Resolved

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Non-Interventional
Study/Program
Non-healthcare professional
3133126
73
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
38
(1) PRALSETINIB (S)
Drug withdrawn
Neg
NA
Not Resolved
3134079
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
196
(1) PRALSETINIB (S)
Dose interrupted
Pos
Unk
Resolving
3134811
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
66
(1) PRALSETINIB (S)
Dose interrupted
Neg
NA
Not Resolved
3134819
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
88
(1) PRALSETINIB (S)
Dose not changed
NA
NA
Resolving
3142009
47
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
36
(1) PRALSETINIB (S)
Dose interrupted
Pos
NA
Resolving
3142878
60
Female
NETHERLANDS
Non-Interventional
Pneumonia
NR
192
(1) PRALSETINIB (S)
NR
Unknown
N/A
Resolved

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Study/Program
Non-healthcare professional
3146495
67
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
304
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Not Recovered/Not
Resolved/Ongoing
3146496
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
108
(1) PRALSETINIB (S)
Dose interrupted
Pos
NA
Resolving
3148581
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Herpes zoster
NR
30
(1) PRALSETINIB (S)
Dose interrupted
Pos
Unk
Resolving
3151896
69
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
58
(1) PRALSETINIB (S)
Drug withdrawn
Pos
NA
Resolving
3160540
67
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
61
(1) PRALSETINIB (S)
Drug withdrawn
Neg
NA
Not Resolved
3165945
46
Female
CHINA
Non-Interventional
Study/Program
Healthcare Professional
Pneumonia
NR
188
(1) PRALSETINIB (S)
Dose not changed
nA
NA
Not Resolved

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
3168019
Not reported
Not reported
CHINA
Spontaneous
Non-healthcare professional
Pneumonia fungal

Pneumonia viral
NR

NR
NR

NR
(1) PRALSETINIB (S)
Drug withdrawn

Drug withdrawn
Unk
NA
Unknown

Unknown
3168844
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
24
(1) PRALSETINIB (S)
Dose not changed
NA
NA
Resolving
3171889
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
74
(1) PRALSETINIB (S)
Dose reduced
Positive
NA
Resolving
3171993
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
69
(1) PRALSETINIB (S)
Dose interrupted
Pos
NA
Resolving
3173154
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
76
(1) PRALSETINIB (S)
Drug withdrawn
Pos
NA
Resolving
3173160
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
22
(1) PRALSETINIB (S)
DOse interrupted
Pos
NA
Resolving

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
3178664
60
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
352
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Not Recovered/Not
Resolved/Ongoing
3187200
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Healthcare Professional
Pneumonia
NR
49
(1) PRALSETINIB (S)
Dose interrupted
Positive
Negative
Recovering/Resolving
3189683
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)
NR
Unknown
N/A
Not Reported
3193091
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
76
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Recovering/Resolving
3196805
Not reported
Not reported
CHINA
Non-Interventional
Study/Program
Healthcare Professional
Pneumonia
NR
30
(1) PRALSETINIB (S)
Dose interrupted


Negative
N/A
Not Recovered/Not
Resolved/Ongoing
3200399
63
Female
CHINA
Spontaneous
Non-healthcare professional
Pneumocystis jirovecii
pneumonia


NR
153
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Not Recovered/Not
Resolved/Ongoing
3208819
54
Male
Infection
NR
NR
(1) PRALSETINIB (S)
Dose not changed
N/A

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
UNITED STATES OF
AMERICA
Non-Interventional
Study/Program
Non-healthcare professional
N/A
Not Reported
3210287
45
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
100
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Not Recovered/Not
Resolved/Ongoing
3210415
79
Male
CHILE
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)
NR
Unkown
N/A
Not Reported
3211239
Not reported
Female
UNITED STATES OF
AMERICA
Spontaneous
Non-healthcare professional
Salmonellosis
NR
NR
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Not Reported
3213783
Not reported
Not reported
FINLAND
Spontaneous
Non-healthcare professional
Infection
NR
NR
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Not Reported
3221280
35
Female
CHINA
Non-Interventional
Study/Program
Healthcare Professional
Pneumonia
NR
0
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Not Recovered/Not
Resolved/Ongoing
3224251
Not reported
Not reported
CHINA
Non-Interventional
Pneumonia
NR
NR
(1) PRALSETINIB (S)
NR
Unknown
N/A
Not Reported

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Study/Program
Non-healthcare professional
3224437
68
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)
Dose interrupted
Negative
N/A
Not Recovered/Not
Resolved/Ongoing
3224977
47
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia


NR
37
(1) PRALSETINIB (S)
Dose interrupted


Negative
N/A
Not Recovered/Not
Resolved/Ongoing
3224992
61
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia


NR
308
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Not Recovered/Not
Resolved/Ongoing
3225565
62
Female
UNITED STATES OF
AMERICA
Spontaneous
Non-healthcare professional
Urinary tract infection
NR
NR
(1) PRALSETINIB (S)
NR
Unkown
N/A
Not Reported
3226435
83
Male
CHINA
Spontaneous
Non-healthcare professional
Pneumonia
NR
90
(1) PRALSETINIB (S)
Dose interrupted


Positive
N/A
Recovering/Resolving
3227527
39
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
440
(1) PRALSETINIB (S)
Dose interrupted
Positive
Negative
Recovering/Resolving

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
3230757
Not reported
Female
PERU
Non-Interventional
Study/Program
Non-healthcare professional
Cystitis
NR
NR
(1) PRALSETINIB (S)

(2) PIPERACILLIN\TAZOBACTAM (T)
NR
Unknown
N/A
Not Reported
3243699
64
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
30
(1) PRALSETINIB (S)
NR
Unkown
N/A
Not reported

Not reported
3251309
64
Male
CHINA
Non-Interventional
Study/Program
Healthcare Professional
Pneumonia fungal


NR
495
(1) PRALSETINIB (S)
Dose interrupted
Positive
Unknown
Recovered/Resolved
3274607
76
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
50
(1) PRALSETINIB (S)
Dose interrupted
Positive
Negative
Not Recovered/Not
Resolved/Ongoing

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
3281243
60
Female
NETHERLANDS
Non-Interventional
Study/Program
Healthcare Professional
Urinary tract infection


NR
340
(1) PRALSETINIB (S)

(2) CEFTRIAXONE (T)

(3) ONDANSETRON (T)
NR
Unkown
N/A
Not Recovered/Not
Resolved/Ongoing
3286439
Not reported
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
COVID-19 pneumonia

Pneumonia
NR

NR
49

129
(1) PRALSETINIB (S)
Dose interrupted

Dose interrupted


Positive

Positive
Unknown

Unknown


Recovered/Resolved

Recovered/Resolved
3291325
76
Female
UNITED STATES OF
AMERICA
Non-Interventional
Study/Program
Non-healthcare professional
COVID-19
NR
NR
(1) PRALSETINIB (S)
NR
Unknown
N/A
Not reported
3295286
Not reported
Male
CHINA
Pulmonary tuberculosis
NR
211
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Recovering/Resolving

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Non-Interventional
Study/Program
Healthcare Professional
3298501
Not reported
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia viral
NR
378
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Recovering/Resolving
3298840
Not reported
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
498
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Not Recovered/Not
Resolved/Ongoing
3300012
Not reported
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
131
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Recovered/Resolved
3300142
Not reported
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
261
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Not Recovered/Not
Resolved/Ongoing
3300849
Not reported
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
455
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Not Recovered/Not
Resolved/Ongoing
3301382
Not reported
Female
CHINA
Non-Interventional
Pneumonia bacterial
NR
594
(1) PRALSETINIB (S)
Dose interrupted
Unknown
N/A


Not reported

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Study/Program
Non-healthcare professional
3301413
Not reported
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
730
(1) PRALSETINIB (S)

(2) ALBUMIN HUMAN (T)
Dose not changed
N/A
N/A
Recovering/Resolving
3308634
49
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
60
(1) PRALSETINIB (S)
Dose interrupted


Positive
N/A
Recovering/Resolving
3311852
Not reported
Male
CHINA
Non-Interventional
Study/Program
Healthcare Professional
Pneumonia
NR
100
(1) PRALSETINIB (S)
Dose interrupted
Positive
N/A
Recovering/Resolving
3311910
Not reported
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pulmonary tuberculosis


NR
118
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Recovered/Resolved
3312005
Not reported
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
354
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Recovering/Resolving
3314824
Not reported
Male
Pneumonia
NR
15
(1) PRALSETINIB (S)
Dose interrupted
Positive

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Positive
Recovering/Resolving
3317450
Not reported
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
32
(1) PRALSETINIB (S)
Dose interrupted
Positive
N/A
Recovering/Resolving
3323925
Not reported
Female
SWITZERLAND
Spontaneous
Healthcare Professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)
N/A
N/A
N/A
NR
3329397
Not reported
Male
CHINA
Non-Interventional
Study/Program
Healthcare Professional
Pneumonia fungal
NR
94
(1) PRALSETINIB (S)
Dose interrupted


Unknown
N/A
Not reported

Unknown
3329888
70
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
90
(1) PRALSETINIB (S)
Dose interrupted
Negative
N/A
Not Recovered/Not
Resolved/Ongoing
3329907
Not reported
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia viral
NR
224
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Not reported

Unknown
3332246
Not reported
Male
CHINA
Non-Interventional
Pneumonia
NR
825
(1) PRALSETINIB (S)
Dose interrupted


Positive

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Study/Program
Non-healthcare professional
N/A
Recovered/Resolved
3332358
Not reported
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
0
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Recovering/Resolving
3333031
Not reported
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
30
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Unknown
3335188
71
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
413
(1) PRALSETINIB (S)
Dose interrupted
Negative
N/A
Not Recovered/Not
Resolved/Ongoing
3339577
Not reported
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
202
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Recovering/Resolving
3347633
Not reported
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
117
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Not Recovered/Not
Resolved/Ongoing
3350871
Not reported
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Bacterial infection
NR
203
(1) PRALSETINIB (S)
Dose interrupted
Positive
N/A
Recovering/Resolving

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
3353260
48
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)
NR
Unknown
Unknown
Unknown
3363056
Not reported
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
42
(1) PRALSETINIB (S)
Dose interrupted
Negative
N/A
Not Recovered/Not
Resolved/Ongoing
3363172
67
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pulmonary tuberculosis
NR
NR
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Recovering/Resolving
3373829
75
Male
CHINA
Spontaneous
Non-healthcare professional
Pneumonia
NR
25
(1) PRALSETINIB (S)
Dose interrupted


Positive
N/A
Recovering/Resolving
3374161
57
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)

(2) METHYLPREDNISOLONE (T)
Dose interrupted
Positive
Negative
 Recovered/Resolved
3376141
Not reported
Female
CHINA
Non-Interventional
Pneumonia bacterial
NR
72
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Recovering/Resolving

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Study/Program
Non-healthcare professional
3376203
Not reported
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
71
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Not Recovered/Not
Resolved/Ongoing
3376828
Not reported
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia fungal
NR
116
(1) PRALSETINIB (S)
Dose interrupted
Positive
N/A
Recovered/Resolved
3379141
Not reported
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
22
(1) PRALSETINIB (S)
Dose interrupted
Positive
N/A
Recovered/Resolved
3381878
Not reported
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
114
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Recovered/Resolved
3383991
Not reported
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pulmonary tuberculosis
NR
591
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Not Recovered/Not
Resolved/Ongoing
3386716
Not reported
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
10
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Recovered/Resolved

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
3387504
Not reported
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia viral
NR
53
(1) PRALSETINIB (S)
Dose interrupted
Positive
N/A
Recovering/Resolving
3389346
Not reported
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia bacterial
NR
41
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Recovering/Resolving
3397054
Not reported
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia viral
NR
82
(1) PRALSETINIB (S)
Dose interrupted
Positive
N/A
Recovering/Resolving
3398505
Not reported
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
29
(1) PRALSETINIB (S)
Dose interrupted


Positive
N/A
Recovering/Resolving
3401655
71
Male
CHINA
Spontaneous
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)
NR
Unknown
N/A
Recovering/Resolving
3401824
80
Female
UNITED STATES OF
AMERICA
Non-Interventional
Study/Program
Non-healthcare professional
Cystitis
NR
NR
(1) PRALSETINIB (S)
NR
Unknown
N/A
Not Reported
3402300
Not reported
Pneumonia
NR
180
(1) PRALSETINIB (S)
Dose interrupted
Unknown

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
N/A
Not Reported
3409827
65
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
395
(1) PRALSETINIB (S)
Dose interrupted
Positive
Unknown
Recovered/Resolved
3411505
71
Female
CHINA
Spontaneous
Non-healthcare professional
Renal abscess
NR
NR
(1) PRALSETINIB (S)
Dose interrupted
Positive
N/A
Recovering/Resolving
3412987
80
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
90
(1) PRALSETINIB (S)
Dose interrupted
Positive
Unknown
Recovered/Resolved
3428310
76
Male
CHINA
Spontaneous
Non-healthcare professional
 Pneumonia
NR
0
(1) PRALSETINIB (S)
Dose interrupted


Positive
N/A
Recovering/Resolving
3429005
59
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Herpes zoster
NR
NR
(1) PRALSETINIB (S)
Dose interrupted

Dose interrupted


Positive

Positive
Unknown

Unknown

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome

Recovering/Resolving
3442167
70
Male
ECUADOR
Non-Interventional
Study/Program
Non-healthcare professional
Pneumocystis jirovecii
pneumonia


NR
NR
(1) PRALSETINIB (S)
NR
Unknown
N/A
Recovering/Resolving
3446901
57
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
365
(1) PRALSETINIB (S)
Dose interrupted


Positive
N/A


Recovered/Resolved
3447575
Not reported
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia

Pneumonia
NR

NR
95

581
(1) PRALSETINIB (S)
Dose not changed

Dose not changed
N/A

N/A

N/A


N/A

N/A

N/A


 Recovered/Resolved

Unknown
3447586
Not reported
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)
Dose interrupted
Negative
N/A
Not Recovered/Not
Resolved/Ongoing

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
3448189
70
Female
UNITED STATES OF
AMERICA
Non-Interventional
Study/Program
Healthcare Professional
Localised infection
NR
1095
(1) PRALSETINIB (S)
NR
Unknown
N/A
 Recovered/Resolved
3449732
Not reported
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)
Dose interrupted
Unknown
N/A
Not Reported
3449782
67
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
90
(1) PRALSETINIB (S)
Dose interrupted
Positive
N/A
Recovered/Resolved
3451085
75
Female
UNITED STATES OF
AMERICA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)
NR
Unknown
N/A
Not Reported
3455222
84
Male
UNITED STATES OF
AMERICA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
30
(1) PRALSETINIB (S)
NR
Unknown
N/A
Not Recovered/Not
Resolved/Ongoing

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
3456562
55
Male
CHINA
Literature - Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)

(2) CASPOFUNGIN (T)

(3) GANCICLOVIR (T)

(4) MEROPENEM (T)
Dose interrupted
Positive
N/A
Recovered/Resolved
3457446
34
Female
CHINA
Literature - Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)

(2) GANCICLOVIR (T)

(3) MOXIFLOXACIN (T)
Dose interrupted
Positive
N/A
Recovered/Resolved

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
3457456
47
Female
CHINA
Literature - Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)

(2) CASPOFUNGIN (T)

(3) GANCICLOVIR (T)

(4) MOXIFLOXACIN (T)

(5)
SULFAMETHOXAZOLE\TRIMETHOPRIM
(T)
Dose interrupted
Positive
N/A
Recovered/Resolved

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
3457457
44
Female
CHINA
Literature - Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)

(2) CEFTAZIDIME (T)

(3) MOXIFLOXACIN (T)

(4)
SULFAMETHOXAZOLE\TRIMETHOPRIM
(T)
Dose interrupted
Positive
N/A
Recovered/Resolved
3457458
64
Female
CHINA
Literature - Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)

(2) GANCICLOVIR (T)

(3) MEROPENEM (T)
Dose interrupted
Positive
N/A
Recovered/Resolved

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
3457459
81
Male
CHINA
Literature - Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)

(2) VORICONAZOLE (T)

(3) FLUCONAZOLE (T)

(4) VANCOMYCIN (T)
Dose interrupted
Positive
N/A
Recovered/Resolved

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
3457460
57
Female
CHINA
Literature - Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)

(2) GANCICLOVIR (T)

(3) MEROPENEM (T)

(4) VORICONAZOLE (T)

(5) MOXIFLOXACIN (T)
Dose interrupted
Positive
N/A
Recovered/Resolved
3457461
57
Female
CHINA
Literature - Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)

(2)
SULFAMETHOXAZOLE\TRIMETHOPRIM
(T)
Dose interrupted
Positive
N/A
Recovered/Resolved

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
3469324
61
Female
CHINA
Literature Spontaneous
Healthcare Professional
Oral candidiasis
NR
52
(1) PRALSETINIB (I)

(2) FLUCONAZOLE (I)
Dose interrupted
Positive
Negative
Recovering/Resolving
3470875
82
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
365
(1) PRALSETINIB (S)
NR
Unknown
N/A
Recovering/Resolving
3472483
80
Female
UNITED STATES OF
AMERICA
Non-Interventional
Study/Program
Non-healthcare professional
Diverticulitis intestinal
perforated
NR
NR
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Not Recovered/Not
Resolved/Ongoing
3474852
Not reported
Male
CHINA
Non-Interventional
Study/Program
Healthcare Professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)
Dose interrupted
Positive
N/A
 Recovered/Resolved
3500767
71
Male
UNITED STATES OF
AMERICA
Spontaneous
Healthcare Professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)

(2) ERYTHROPOIETIN (C)
Dose interrupted
Unknown
N/A
Not Reported

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
3538667
61
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Fungal infection
NR
66
(1) PRALSETINIB (S)
Dose interrupted
Positive
N/A
Recovering/Resolving
3542163
Not reported
Female
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia fungal
NR
91
(1) PRALSETINIB (S)
Dose interrupted
Positive
Positive
Recovered/Resolved
3566427
65
Male
CANADA
Spontaneous
Non-healthcare professional
Cellulitis
NR
NR
(1) PRALSETINIB (S)

(2) SELPERCATINIB (S)

(3) OCTREOTIDE (C)
NR
Unknown
N/A
Not reported
3566459
78
Male
NEW ZEALAND
Spontaneous
Healthcare Professional
Pneumocystis jirovecii
pneumonia
NR
58
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Recovered/Resolved
3573082
Not reported
Not reported
UNITED STATES OF
AMERICA
Literature - Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia cytomegaloviral
NR
NR
(1) PRALSETINIB (S)
NR
Unknown
N/A
Not Reported

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
3573396
Not reported
Not reported
UNITED STATES OF
AMERICA
Literature - Non-Interventional
Study/Program
Non-healthcare professional
Bronchopulmonary
aspergillosis
NR
NR
(1) PRALSETINIB (S)
Dose interrupted
Unknown
Unknown
Not Reported
3573997
Not reported
Not reported
UNITED STATES OF
AMERICA
Literature - Non-Interventional
Study/Program
Non-healthcare professional
Bronchopulmonary
aspergillosis
NR
NR
(1) PRALSETINIB (S)
Dose interrupted
Unknown
Unknown
Not Reported
3574008
Not reported
Not reported
UNITED STATES OF
AMERICA
Literature - Non-Interventional
Study/Program
Non-healthcare professional
Bronchopulmonary
aspergillosis
NR
NR
(1) PRALSETINIB (S)
Dose interrupted
Unknown
Unknown
Not Reported
10000022729
Not reported
Female
UNITED KINGDOM
Spontaneous
Non-healthcare professional
Gangrene
NR
NR
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Not Reported
10000029822
73
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia
NR
30
(1) PRALSETINIB (S)
Dose interrupted
Positive
N/A
Recovering/Resolving

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to
Onset
(in days)
Drug type (All)
Action Taken
Dechallenge
Rechallenge
Event Outcome
10000042220
45
Male
UNITED STATES OF
AMERICA
Spontaneous
Non-healthcare professional
Pneumonia
NR
NR
(1) PRALSETINIB (S)

(2) LEVOTHYROXINE SODIUM (C)
Dose interrupted
Positive
N/A
Recovering/Resolving
2902724
83
Female
CHILE
Non-Interventional
Study/Program
Healthcare Professional
Pneumonia

Sepsis
NR

Grade 5
0

0
(1) ALECTINIB (S)

(2) PRALSETINIB (S)
NR

NR
Unknown

Unknown
N/A

N/A
Not Reported

Fatal
2941403
63
Female
HUNGARY
Non-Interventional
Study/Program
Healthcare Professional
Herpes virus infection

Peritonitis


NR

Grade 5
78

NR
(1) PRALSETINIB (S)
Dose interrupted

Dose interrupted
N/A
N/A
NR

Fatal
3360718
Not reported
Male
CHINA
Non-Interventional
Study/Program
Non-healthcare professional
Pneumonia

Pneumonia
Grade 5

NR
24
(1) PRALSETINIB (S)
Dose not changed
N/A
N/A
Fatal

Recovering/Resolving


79
Drug Safety Report No: 1132062
Appendix 8
Case Listings Reporting Grade 1 and 2 Infections from the
Company Safety Database (N=73)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
2709793
58
Female
FRANCE
Clinical
Study
Healthcare
Professional
Gastroenteriti
s
Grade 2
17
(1) PRALSETINIB (S)

(2) MACROGOL 3350\POTASSIUM CHLORIDE\SODIUM BICARBONATE\SODIUM CHLORIDE
(C)

(3) ALPRAZOLAM (C)

(4) OXYCODONE HYDROCHLORIDE (C)

(5) OXYCODONE HYDROCHLORIDE (C)

(6) OXYCODONE HYDROCHLORIDE (C)

(7) PREDNISONE (C)

(8) PARACETAMOL (C)

(9) OLODATEROL HYDROCHLORIDE\TIOTROPIUM BROMIDE MONOHYDRATE (C)

(10) GABAPENTIN (C)

(11) LEVOTHYROXINE (C)

(12) PANTOPRAZOLE (C)

(13) LOPERAMIDE (C)

(14) DIOSMECTITE (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
2709974
59
Female
FRANCE
Clinical
Study
Healthcare
Professional
Urinary tract
infection
Grade 2
59
(1) PRALSETINIB (S)

(2) GABAPENTIN (C)

(3) LEVOTHYROXINE SODIUM (C)

(4) POTASSIUM CHLORIDE (C)

(5) OXYCODONE HYDROCHLORIDE (C)

(6) MAGNESIUM CARBONATE (C)

(7) AMOXICILLIN (C)

(8) OLODATEROL HYDROCHLORIDE\TIOTROPIUM BROMIDE MONOHYDRATE (C)

(9) HYDROCORTISONE (C)

(10) PREDNISOLONE METASULFOBENZOATE SODIUM (C)

(11) PARACETAMOL (C)

(12) PACLITAXEL (C)

(13) OXYCODONE HYDROCHLORIDE (C)

(14) BEVACIZUMAB (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)

(15) CEFOTAXIME SODIUM (T)
2716439
68
Male
KOREA,
REPUBLIC
OF
Clinical
Study
Healthcare
Professional
Pneumocysti
s jirovecii
pneumonia
Grade 2
48
(1) PRALSETINIB (S)

(2) LEVOTHYROXINE (C)

(3) AMLODIPINE (C)

(4) CHLORPHENAMINE MALEATE (C)

(5) PARACETAMOL (C)

(6) SULFAMETHOXAZOLE\TRIMETHOPRIM (T)

(7) METHYLPREDNISOLONE SODIUM SUCCINATE (T)
2717157
56
Male
CHINA
Clinical
Study
Non-
healthcare
professional
Pneumonia
Grade 2
25
(1) PRALSETINIB (S)

(2) ENTECAVIR (C)

(3) ZOLEDRONIC ACID (C)

(4) MOXIFLOXACIN (T)

(5) LINEZOLID (T)
2717924
50
Male
CHINA
Febrile
infection
Grade 1
186
(1) PRALSETINIB (S)

(2) ERYTHROPOIETIN HUMAN (C)


AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
Clinical
Study
Healthcare
Professional
(3) METOPROLOL (C)

(4) PIPERACILLIN SODIUM\TAZOBACTAM SODIUM (C)

(5) CEFOPERAZONE SODIUM\SULBACTAM SODIUM (C)

(6) ACETYLCYSTEINE (C)
2719510
68
Female
CHINA
Clinical
Study
Healthcare
Professional
Skin infection
Grade 2
34
(1) PRALSETINIB (S)

(2) LEUCOGEN (C)

(3) AMOXICILLIN TRIHYDRATE\CLAVULANATE POTASSIUM (C)

(4) DEXTROMETHORPHAN HYDROBROMIDE (C)

(5) FOLIC ACID (C)

(6) SPIRONOLACTONE (C)

(7) FUROSEMIDE (C)

(8) CEFOPERAZONE SODIUM\SULBACTAM SODIUM (C)

(9) ALBUMIN HUMAN (C)

(10) CILASTATIN SODIUM\IMIPENEM (C)

(11) VANCOMYCIN HYDROCHLORIDE (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)

(12) DESONIDE (C)

(13) LINEZOLID (C)

(14) INDOMETACIN (T)

(15) IBUPROFEN (T)
2724162
51
Female
KOREA,
REPUBLIC
OF
Non-
Interventional
Study/Progra
m
Healthcare
Professional
Peritoneal
tuberculosis
Grade 2
(1) (1)
104

(1) (3)
183
(1) PRALSETINIB (S)

(2) LEVOTHYROXINE (C)

(3) ISONIAZID (T)

(4) RIFABUTIN (T)

(5) ETHAMBUTOL (T)

(6) PYRAZINAMIDE (T)

(7) PYRIDOXINE HYDROCHLORIDE (T)
2728333
66
Female
FRANCE
Clinical
Study
Cellulitis
Grade 2
603
(1) PRALSETINIB (S)

(2) HYDROCORTISONE (C)

(3) LEVOTHYROXINE (C)

(4) MACROGOL 3350\POTASSIUM CHLORIDE\SODIUM BICARBONATE\SODIUM CHLORIDE

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
Healthcare
Professional
(C)

(5) PARACETAMOL (C)

(6) COLECALCIFEROL (C)

(7) DICLOFENAC (C)

(8) PARACETAMOL (C)

(9) TRAMADOL HYDROCHLORIDE (C)

(10) CLOXACILLIN (C)

(11) OFLOXACIN (C)

(12) RIFAMPICIN (C)
2729086
58
Female
FRANCE
Clinical
Study
Healthcare
Professional
Escherichia
urinary tract
infection
Grade 2
40
(1) PRALSETINIB (S)

(2) OXYCODONE HYDROCHLORIDE (C)

(3) LOPERAMIDE (C)

(4) DIOSMECTITE (C)

(5) GABAPENTIN (C)
2730635
83
Pneumonia
pneumococc
45
(1) PRALSETINIB (S)


AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
Female
ITALY
Clinical
Study
Non-
healthcare
professional
al
Grade 2
(2) RAMIPRIL (C)

(3) AMLODIPINE BESILATE (C)

(4) METHYLPREDNISOLONE (C)

(5) PANTOPRAZOLE (C)

(6) CEFTRIAXONE (T)

(7) AZITHROMYCIN (T)

(8) HEPARIN (T)

(9) OXYGEN (T)
2735584
58
Male
SPAIN
Clinical
Study
Healthcare
Professional
Atypical
pneumonia

Pneumocysti
s jirovecii
pneumonia
Grade 2

Grade 2
148

47
(1) PRALSETINIB (S)

(2) METAMIZOLE (C)

(3) FILGRASTIM (C)

(4) OMEPRAZOLE (C)

(5) ANASTROZOLE (C)

(6) LEVOFLOXACIN (T)

(7) MEROPENEM (T)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)

(8) PARACETAMOL (T)

(9) LINEZOLID (T)

(10) BEMIPARIN SODIUM (T)

(11) OMEPRAZOLE (T)

(12) IPRATROPIUM BROMIDE (T)

(13) BUDESONIDE (T)

(14) SULFAMETHOXAZOLE\TRIMETHOPRIM (T)

(15) GANCICLOVIR (T)

(16) LINEZOLID (T)

(17) METOCLOPRAMIDE (T)

(18) SULFAMETHOXAZOLE\TRIMETHOPRIM (T)

(19) VORICONAZOLE (T)

(20) PREDNISONE (T)

(21) SULFAMETHOXAZOLE\TRIMETHOPRIM (T)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
2744518
68
Male
CHINA
Clinical
Study
Healthcare
Professional
Tuberculosis
Grade 2
91
(1) PRALSETINIB (S)

(2) METOPROLOL (C)

(3) ATORVASTATIN CALCIUM (C)

(4) ACETYLSALICYLIC ACID (C)

(5) METHYLPREDNISOLONE SODIUM SUCCINATE (C)

(6) UMIFENOVIR (C)

(7) ISONIAZID (C)

(8) ETHAMBUTOL DIHYDROCHLORIDE (C)

(9) MOXIFLOXACIN (C)

(10) MOXIFLOXACIN HYDROCHLORIDE (C)

(11) LINEZOLID (T)
2755070
54
Male
UNITED
STATES OF
AMERICA
Clinical
Atypical
mycobacteria
l pneumonia
Grade 2
730
(1) PRALSETINIB (S)

(2) AZITHROMYCIN (C)

(3) ETHAMBUTOL (C)

(4) MOXIFLOXACIN (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
Study
Non-
healthcare
professional

(5) RIFAMPICIN (C)

(6) LEVETIRACETAM (C)

(7) RIFABUTIN (C)

(8) ACETYLSALICYLIC ACID (C)

(9) COLECALCIFEROL (C)

(10) ESOMEPRAZOLE (C)

(11) PLANTAGO OVATA (C)

(12) METFORMIN (C)

(13) PYRIDOXINE (C)

(14) ROSUVASTATIN (C)
2755509
59
Female
FRANCE
Clinical
Study
Healthcare
Professional
Bronchopulm
onary
aspergillosis
Grade 2
261
(1) PRALSETINIB (S)

(2) FORMOTEROL FUMARATE (C)

(3) ZOLMITRIPTAN (C)

(4) CARBOMER (C)


AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
(5) AMPHOTERICIN B (C)

(6) PARACETAMOL (C)

(7) TRAMADOL (C)

(8) METOCLOPRAMIDE HYDROCHLORIDE (C)

(9) FOSFOMYCIN TROMETAMOL (C)

(10) FLUTICASONE PROPIONATE (C)

(11) SODIUM BICARBONATE (C)

(12) ENOXAPARIN SODIUM (T)

(13) MIDAZOLAM HYDROCHLORIDE (T)

(14) ALPRAZOLAM (T)

(15) ISAVUCONAZONIUM SULFATE (T)
2758736
27
Female
UNITED
STATES OF
AMERICA
Clinical
Upper
respiratory
tract infection
Grade 2

(1) PRALSETINIB (S)

(2) PARACETAMOL (C)

(3) CYCLOBENZAPRINE HYDROCHLORIDE (C)

(4) GABAPENTIN (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
Study
Non-
healthcare
professional

(5) HYDROCODONE BITARTRATE\PARACETAMOL (C)

(6) LEVOTHYROXINE SODIUM (C)

(7) MORPHINE SULFATE (C)

(8) SUMATRIPTAN (C)

(9) ZOLPIDEM TARTRATE (C)

(10) DIAZEPAM (C)

(11) DOXAZOSIN MESILATE (C)

(12) ENOXAPARIN (C)

(13) SODIUM CHLORIDE (T)

(14) KETOROLAC TROMETHAMINE (T)

(15) MORPHINE (T)

(16) GABAPENTIN (T)

(17) LEVOTHYROXINE (T)

(18) IPRATROPIUM BROMIDE\SALBUTAMOL SULFATE (T)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)

(19) OSELTAMIVIR (T)

(20) ZOLPIDEM (T)

(21) CYCLOBENZAPRINE (T)

(22) DIPHENHYDRAMINE (T)

(23) HYDROCODONE BITARTRATE\PARACETAMOL (T)

(24) ONDANSETRON (T)
2772612
57
Female
KOREA,
REPUBLIC
OF
Non-
Interventional
Study/Progra
m
Non-
healthcare
professional
Lymph node
tuberculosis
Grade 2
(1) (1) 51
(1) PRALSETINIB (S)

(2) METOCLOPRAMIDE (C)
2788572
67
Female
Lymph node
tuberculosis

131

165
(1) PRALSETINIB (S)

(2) RAMIPRIL (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
GERMANY
Clinical
Study
Healthcare
Professional
Lymph node
tuberculosis
Grade 1

Grade 1

(3) AMLODIPINE (C)

(4) DEXPANTHENOL (C)

(5) SODIUM CHLORIDE (C)

(6) PANTOPRAZOLE (C)

(7) ACETYLSALICYLIC ACID (C)

(8) TICAGRELOR (C)

(9) FONDAPARINUX SODIUM (C)

(10) METOPROLOL (C)

(11) NITRENDIPINE (C)

(12) ETHAMBUTOL DIHYDROCHLORIDE (T)

(13) RIFAMPICIN (T)

(14) PYRAZINAMIDE (T)
2788593
65
Male
SPAIN
Urinary tract
infection
Grade 2
41
(1) PRALSETINIB (S)

(2) ENALAPRIL (C)


AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
Clinical
Study
Non-
healthcare
professional
(3) ACETYLSALICYLIC ACID (C)

(4) TICAGRELOR (C)

(5) BISOPROLOL (C)

(6) LEVOTHYROXINE (C)

(7) ROSUVASTATIN (C)

(8) ESOMEPRAZOLE (C)

(9) PREGABALIN (C)
2788685
36
Male
CHINA
Clinical
Study
Non-
healthcare
professional
Gastroenteriti
s
Grade 2
167
(1) PRALSETINIB (S)

(2) OSELTAMIVIR PHOSPHATE (C)

(3) POTASSIUM CHLORIDE (C)

(4) PYRIDOXINE HYDROCHLORIDE (C)

(5) ASCORBIC ACID (C)

(6) ZINC GLUCONATE (C)

(7) IRON DEXTRAN (C)

(8) LOXOPROFEN SODIUM (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)

(9) BACILLUS SUBTILIS\ENTEROCOCCUS FAECALIS\LACTOBACILLUS ACIDOPHILUS (C)

(10) CYSTEINE HYDROCHLORIDE\GLYCINE\GLYCYRRHIZIC ACID, AMMONIUM SALT (C)
2793669
57
Female
ITALY
Clinical
Study
Healthcare
Professional
Pneumonia
Grade 2
139
(1) PRALSETINIB (S)

(2) PARACETAMOL (C)

(3) MAGNESIUM SULFATE (C)

(4) PANTOPRAZOLE (C)

(5) FERROUS SULFATE (C)

(6) PREDNISONE (C)

(7) FLUCONAZOLE (C)

(8) NYSTATIN (C)

(9) FOLINIC ACID (C)
2797075
71
Female
ITALY
Clinical
Study
Pneumonia
Grade 2
21
(1) PRALSETINIB (S)

(2) TRIAZOLAM (C)

(3) PREDNISONE (C)

(4) OMEPRAZOLE (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
Healthcare
Professional

(5) BUDESONIDE\FORMOTEROL FUMARATE (C)

(6) COLECALCIFEROL (C)

(7) BECLOMETASONE DIPROPIONATE (C)

(8) FONDAPARINUX (C)

(9) TRAMADOL (C)

(10) SODIUM ALGINATE (C)

(11) SODIUM BICARBONATE (C)

(12) LORAZEPAM (C)

(13) FOLIC ACID (C)

(14) GLUCOSE (C)

(15) SODIUM CHLORIDE (C)

(16) GLUTATHIONE (C)

(17) DEXAMETHASONE (C)

(18) POTASSIUM CHLORIDE (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)

(19) BECLOMETASONE DIPROPIONATE (C)

(20) MICONAZOLE (C)

(21) THIAMPHENICOL (C)

(22) LEVOFLOXACIN (C)

(23) PARACETAMOL (C)

(24) CODEINE PHOSPHATE\PARACETAMOL (C)

(25) AMOXICILLIN (C)

(26) TRIAZOLAM (C)

(27) OMEPRAZOLE (C)

(28) COLECALCIFEROL (C)

(29) PIPERACILLIN SODIUM\TAZOBACTAM SODIUM (T)

(30) METHYLPREDNISOLONE SODIUM SUCCINATE (T)

(31) OXYGEN (T)
2797540
57
Pneumonia
Grade 2
63
(1) PRALSETINIB (S)


AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
Male
KOREA,
REPUBLIC
OF
Clinical
Study
Healthcare
Professional
(2) ISOSORBIDE MONONITRATE (C)

(3) CILAZAPRIL (C)

(4) AMMONIUM CHLORIDE\CHLORPHENAMINE MALEATE\DIHYDROCODEINE
BITARTRATE\METHYLEPHEDRINE HYDROCHLORIDE-DL (C)

(5) DEXAMETHASONE (C)

(6) FENTANYL CITRATE (C)

(7) SODIUM BICARBONATE (C)

(8) NYSTATIN (C)

(9) LIDOCAINE (C)

(10) POVIDONE-IODINE (C)

(11) CLONAZEPAM (C)

(12) LACTULOSE (C)

(13) ESOMEPRAZOLE MAGNESIUM\NAPROXEN (C)

(14) ALANINE\ARGININE\ASPARTIC ACID\CYSTEINE\GLUTAMIC
ACID\GLYCINE\HISTIDINE\ISOLEUCINE\LEUCINE\LYSINE
ACETATE\METHIONINE\PHENYLALANINE\PROLINE\SERINE\THREONINE\TRYPTOPHAN\TY

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
ROSINE\VALINE (C)

(15) SODIUM SELENITE PENTAHYDRATE (C)

(16) MORPHINE HYDROCHLORIDE (T)

(17) AMPICILLIN SODIUM\SULBACTAM SODIUM (T)

(18) PIPERACILLIN SODIUM\TAZOBACTAM SODIUM (T)

(19) LEVOFLOXACIN (T)

(20) PROPACETAMOL HYDROCHLORIDE (T)

(21) MORPHINE (T)

(22) TIROPRAMIDE HYDROCHLORIDE (T)
2797904
57
Female
UNITED
STATES OF
AMERICA
Clinical
Study
Healthcare
Professional
Pneumonia
Grade 2
28
(1) PRALSETINIB (S)

(2) ALPRAZOLAM (C)

(3) AMLODIPINE (C)

(4) COLECALCIFEROL (C)

(5) LEVOTHYROXINE (C)

(6) VANCOMYCIN (T)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)

(7) PIPERACILLIN SODIUM\TAZOBACTAM SODIUM (T)
2798534
61
Male
UNITED
STATES OF
AMERICA
Clinical
Study
Non-
healthcare
professional
Viral infection
Grade 2
289
(1) PRALSETINIB (S)

(2) BENZONATATE (C)

(3) CALCIUM CITRATE\COLECALCIFEROL (C)

(4) BETAMETHASONE DIPROPIONATE\CLOTRIMAZOLE (C)

(5) MELATONIN (C)

(6) TRAMADOL (C)

(7) DIPHENHYDRAMINE (C)

(8) DENOSUMAB (C)

(9) TAMSULOSIN (C)

(10) RIBOFLAVIN (C)

(11) LOPERAMIDE (C)

(12) OMEPRAZOLE (C)

(13) MAGNESIUM OXIDE (C)


AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
(14) SILDENAFIL (C)

(15) PANTOPRAZOLE (C)

(16) METHYLPREDNISOLONE (C)

(17) MORPHINE (C)

(18) ONDANSETRON (C)

(19) CALCIUM CHLORIDE DIHYDRATE\GLUCOSE\POTASSIUM CHLORIDE\SODIUM
CHLORIDE\SODIUM LACTATE (C)

(20) HYDROMORPHONE (C)

(21) ENOXAPARIN (C)

(22) SODIUM PHOSPHATE DIBASIC\SODIUM PHOSPHATE MONOBASIC (ANHYDROUS) (C)

(23) BACLOFEN (C)

(24) GABAPENTIN (C)

(25) OXYCODONE (C)

(26) PROCHLORPERAZINE EDISYLATE (C)

(27) PARACETAMOL (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)

(28) ONDANSETRON (C)
2799334
74
Male
SPAIN
Non-
Interventional
Study/Progra
m
Healthcare
Professional
Cytomegalov
irus infection
Grade 2
(1) (3) 28
(1) PRALSETINIB (S)

(2) ATENOLOL (C)

(3) CHLORTALIDONE (C)

(4) ENOXAPARIN (C)

(5) DEXAMETHASONE (C)

(6) CISPLATIN (C)

(7) VINORELBINE (C)

(8) OMEPRAZOLE (T)

(9) GANCICLOVIR (T)

(10) FOSCARNET (T)
2799583
58
Female
UNITED
STATES OF
AMERICA
Clinical
Pneumonia
Grade 2
553
(1) PRALSETINIB (S)

(2) BENZONATATE (C)

(3) PARACETAMOL (C)

(4) NAPROXEN (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
Study
Healthcare
Professional

(5) LIDOCAINE (C)

(6) METFORMIN (C)
2800555
65
Male
SPAIN
Clinical
Study
Non-
healthcare
professional
Urinary tract
infection
Grade 2
154
(1) PRALSETINIB (S)

(2) ACETYLSALICYLIC ACID (C)

(3) LEVOTHYROXINE (C)

(4) TAMSULOSIN HYDROCHLORIDE (C)

(5) BISOPROLOL (C)

(6) ESOMEPRAZOLE (C)

(7) FOSFOMYCIN (C)

(8) COLECALCIFEROL (C)

(9) TICAGRELOR (C)

(10) PYRIDOSTIGMINE (C)

(11) PIPERACILLIN (T)
2800581
59
Female
Bacteraemia

COVID-19
77

82
(1) PRALSETINIB (S)

(2) ZOLPIDEM (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
SPAIN
Clinical
Study
Healthcare
Professional
pneumonia
Grade 2

Grade 2

(3) MELATONIN (C)

(4) ESCITALOPRAM (C)

(5) PARACETAMOL (C)

(6) LIDOCAINE (C)

(7) NYSTATIN (C)

(8) SODIUM BICARBONATE (C)

(9) DEXAMETHASONE (C)

(10) CEFTRIAXONE (T)

(11) CLOXACILLIN (T)

(12) CIPROFLOXACIN (T)

(13) DAPTOMYCIN (T)

(14) AZITHROMYCIN (T)

(15) HYDROXYCHLOROQUINE SULFATE (T)

(16) TEICOPLANIN (T)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)

(17) ANAKINRA (T)

(18) TOCILIZUMAB (T)
2800611
67
Male
KOREA,
REPUBLIC
OF
Clinical
Study
Non-
healthcare
professional
Sepsis
Grade 2
50
(1) PRALSETINIB (S)

(2) ARGININE HYDROCHLORIDE\IBUPROFEN (C)

(3) PIPERACILLIN SODIUM\TAZOBACTAM SODIUM (T)

(4) AZITHROMYCIN (T)

(5) CIPROFLOXACIN (T)
2800633
64
Male
GERMANY
Non-
Interventional
Study/Progra
m
Healthcare
Professional
Pneumonia
bacterial

Spontaneous
bacterial
peritonitis
Grade 1

Grade 1
(1) (1)
531

(1) (2)
531
(1) PRALSETINIB (S)

(2) LEVOTHYROXINE (C)

(3) FUROSEMIDE (C)

(4) SITAGLIPTIN (C)

(5) COLECALCIFEROL (C)
2800727
68
Male
Escherichia
urinary tract
859
(1) PRALSETINIB (S)

(2) ERGOCALCIFEROL (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
UNITED
STATES OF
AMERICA
Clinical
Study
Healthcare
Professional
infection
Grade 2

(3) KETOCONAZOLE (C)

(4) MUPIROCIN (C)

(5) NAPROXEN SODIUM (C)

(6) OXYCODONE HYDROCHLORIDE\PARACETAMOL (C)

(7) PHENAZOPYRIDINE (C)

(8) PREGABALIN (C)

(9) SENNA SPP. (C)

(10) LEVOTHYROXINE SODIUM (C)

(11) TAMSULOSIN (C)

(12) CEFEPIME (T)

(13) LEVOFLOXACIN (T)

(14) VANCOMYCIN (T)
2800846
60
Male
UNITED
Pneumonia
Grade 2
315
(1) PRALSETINIB (S)

(2) LEVETIRACETAM (C)


AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
STATES OF
AMERICA
Clinical
Study
Non-
healthcare
professional
(3) FUROSEMIDE (T)

(4) AZITHROMYCIN (T)

(5) CHLORHEXIDINE (T)
2801034
Not reported
Female
UNITED
STATES OF
AMERICA
Clinical
Study
Non-
healthcare
professional
Upper
respiratory
tract infection
Grade 2
Not
reported
(1) PRALSETINIB (S)

(2) PARACETAMOL (C)

(3) CYCLOBENZAPRINE HYDROCHLORIDE (C)

(4) GABAPENTIN (C)

(5) HYDROCODONE BITARTRATE\PARACETAMOL (C)

(6) LEVOTHYROXINE SODIUM (C)

(7) MORPHINE SULFATE (C)

(8) SUMATRIPTAN (C)

(9) ZOLPIDEM TARTRATE (C)

(10) DIAZEPAM (C)

(11) DOXAZOSIN MESILATE (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)

(12) MORPHINE (C)

(13) ENOXAPARIN (C)

(14) KETOROLAC TROMETHAMINE (T)

(15) GABAPENTIN (T)

(16) IPRATROPIUM BROMIDE\SALBUTAMOL SULFATE (T)

(17) LEVOTHYROXINE (T)

(18) OSELTAMIVIR (T)

(19) ZOLPIDEM (T)

(20) CYCLOBENZAPRINE (T)

(21) DIPHENHYDRAMINE (T)

(22) HYDROCODONE BITARTRATE\PARACETAMOL (T)

(23) ONDANSETRON (T)
2801426
32
Male
CHINA
Pneumonia
influenzal
Grade 2
42
(1) PRALSETINIB (S)

(2) GEMCITABINE (C)


AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
Clinical
Study
Healthcare
Professional
(3) NEDAPLATIN (C)

(4) MOXIFLOXACIN HYDROCHLORIDE (C)

(5) POTASSIUM CHLORIDE (C)

(6) OMEPRAZOLE SODIUM (C)

(7) GLUTATHIONE (C)

(8) IMMUNOGLOBULIN HUMAN NORMAL (C)

(9) OSELTAMIVIR PHOSPHATE (T)

(10) METHYLPREDNISOLONE SODIUM SUCCINATE (T)

(11) THYMALFASIN (T)
2802306
71
Female
ITALY
Clinical
Study
Healthcare
Professional
Pneumonia
Grade 2
54
(1) PRALSETINIB (S)

(2) DENOSUMAB (C)

(3) METOPROLOL (C)

(4) ROSUVASTATIN (C)

(5) EDOXABAN (C)

(6) DOXAZOSIN MESILATE (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)

(7) CALCIUM (C)

(8) ALLOPURINOL (C)

(9) COLECALCIFEROL (C)

(10) BROMAZEPAM (C)

(11) RANITIDINE (C)

(12) CLOPIDOGREL (C)

(13) AMLODIPINE (C)

(14) MICONAZOLE (C)

(15) CLOTRIMAZOLE (C)

(16) CEFTRIAXONE (C)

(17) DEXAMETHASONE (C)

(18) RANITIDINE HYDROCHLORIDE (C)

(19) METOCLOPRAMIDE (C)

(20) MORPHINE (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)

(21) TRAMADOL (C)

(22) ENOXAPARIN (C)

(23) MACROGOL 3350\POTASSIUM CHLORIDE\SODIUM BICARBONATE\SODIUM CHLORIDE
(C)

(24) PIPERACILLIN (T)

(25) AZITHROMYCIN (T)
2802338
60
Male
FRANCE
Clinical
Study
Non-
healthcare
professional
Pneumonia
Grade 2
29
(1) PRALSETINIB (S)

(2) LEVOTHYROXINE SODIUM (C)

(3) LOPERAMIDE HYDROCHLORIDE (C)

(4) MORPHINE SULFATE (C)

(5) ALPRAZOLAM (C)

(6) FENTANYL (C)

(7) FLUDROCORTISONE ACETATE (C)

(8) HYDROCORTISONE (C)

(9) GABAPENTIN (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)

(10) LORMETAZEPAM (C)

(11) CODEINE PHOSPHATE\PARACETAMOL (C)

(12) OXYCODONE HYDROCHLORIDE (C)

(13) SALBUTAMOL (C)

(14) RACECADOTRIL (C)

(15) TERBUTALINE SULFATE (T)

(16) IPRATROPIUM BROMIDE (T)

(17) PIPERACILLIN SODIUM\TAZOBACTAM SODIUM (T)

(18) SPIRAMYCIN (T)

(19) SULFAMETHOXAZOLE\TRIMETHOPRIM (T)

(20) PREDNISOLONE METASULFOBENZOATE SODIUM (T)
2802341
68
Female
UNITED
STATES OF
AMERICA
Pneumonia
influenzal
Grade 2
241
(1) PRALSETINIB (S)

(2) LEVOTHYROXINE SODIUM (C)

(3) ALPRAZOLAM (C)


AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
Clinical
Study
Healthcare
Professional
(4) AMLODIPINE BESILATE (C)

(5) CALCIUM CITRATE (C)

(6) COLECALCIFEROL (C)

(7) LOPERAMIDE HYDROCHLORIDE (C)

(8) METOPROLOL SUCCINATE (C)

(9) HYDROCHLOROTHIAZIDE\VALSARTAN (C)

(10) CYANOCOBALAMIN (C)

(11) OMEPRAZOLE (C)

(12) TRAMADOL HYDROCHLORIDE (C)

(13) IBUPROFEN (C)

(14) VANCOMYCIN (T)

(15) MEROPENEM (T)

(16) OSELTAMIVIR PHOSPHATE (T)
2810237
71
Female
Pneumonia
Grade 2
89
(1) PRALSETINIB (S)

(2) FERROUS SULFATE (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
KOREA,
REPUBLIC
OF
Clinical
Study
Healthcare
Professional

(3) AMPHOTERICIN B (C)

(4) MOXIFLOXACIN HYDROCHLORIDE (C)

(5) CARVEDILOL (C)

(6) HEPARIN (C)

(7) METOCLOPRAMIDE (C)

(8) AMLODIPINE BESILATE (C)

(9) PARACETAMOL\TRAMADOL HYDROCHLORIDE (C)

(10) AMINO ACIDS NOS\CALCIUM\GLUCOSE\MAGNESIUM\POTASSIUM\SODIUM (C)

(11) CHROMIC CHLORIDE\COPPER SULFATE\MANGANESE SULFATE\ZINC SULFATE (C)

(12) LOPERAMIDE (C)

(13) SODIUM CHLORIDE (C)

(14) DIOSMECTITE (C)

(15) PANTOPRAZOLE SODIUM SESQUIHYDRATE (C)
2830445
59
Pharyngitis
Grade 2
56
(1) PRALSETINIB (S)


AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
Male
ITALY
Clinical
Study
Healthcare
Professional
(2) ACETYLSALICYLIC ACID (C)

(3) ROSUVASTATIN (C)

(4) CEFTRIAXONE (T)
2867439
69
Female
ITALY
Non-
Interventional
Study/Progra
m
Healthcare
Professional
Herpes
zoster
reactivation


Grade 2
(1) (2)
135
(1) PRALSETINIB (S)

(2) FOLIC ACID (C)

(3) FONDAPARINUX SODIUM (C)

(4) PREDNISONE (C)

(5) FUROSEMIDE (C)

(6) ALPRAZOLAM (C)

(7) FENTANYL (C)

(8) BENSERAZIDE HYDROCHLORIDE\LEVODOPA (C)

(9) DOXYCYCLINE (C)

(10) PREDNISONE (T)
2920551
29
Female
Pneumonia
viral

(1) (1) 58

(1) (2)
(1) PRALSETINIB (S)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
CHINA
Non-
Interventional
Study/Progra
m
Non-
healthcare
professional
Pneumonia
bacterial
Grade 2

Grade 2
2967126
78
Male
ITALY
Non-
Interventional
Study/Progra
m
Healthcare
Professional
Bronchiolitis
Grade 2
(1) (12)
933

(1) (13)
943
(1) PRALSETINIB (S)

(2) CEFTRIAXONE (T)

(3) METHYLPREDNISOLONE (T)

(4) LEVOFLOXACIN (T)

(5) FLUTICASONE FUROATE\VILANTEROL TRIFENATATE (T)

(6) VALACICLOVIR (T)
3015784
37
Male
GERMANY
Clinical
Study
Healthcare
Professional
Psoas
abscess
Grade 1
1095
(1) PRALSETINIB (S)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
3051628
61
Male
KOREA,
REPUBLIC
OF
Clinical
Study
Healthcare
Professional
Pneumonia
Grade 2
361
(1) PRALSETINIB (S)

(2) MAGNESIUM OXIDE (C)

(3) REMDESIVIR (T)

(4) DEXAMETHASONE (T)
3081178
37
Male
GERMANY
Clinical
Study
Healthcare
Professional
COVID-19
Grade 2
1095
(1) PRALSETINIB (S)
3102238
73
Female
UNITED
STATES OF
AMERICA
Clinical
Study
Healthcare
Professional
COVID-19
Grade 1
1095
(1) PRALSETINIB (S)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
3143024
72
Male
KOREA,
REPUBLIC
OF
Clinical
Study
Healthcare
Professional
Postoperativ
e wound
infection
Grade 2
58
(1) PRALSETINIB (S)

(2) VALSARTAN (C)

(3) CODEINE PHOSPHATE\IBUPROFEN\PARACETAMOL (C)

(4) AZELASTINE (C)

(5) CHLORPHENAMINE (C)

(6) MAGNESIUM OXIDE (C)

(7) PANTOPRAZOLE (C)

(8) INSULIN HUMAN (C)

(9) AMBROXOL (C)

(10) CALCIUM GLUCONATE (C)

(11) SODIUM BICARBONATE (C)

(12) ALBUMIN HUMAN (C)

(13) FUROSEMIDE (C)

(14) PARACETAMOL (C)


AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
(15) HYDROMORPHONE (C)

(16) CHLORHEXIDINE (C)

(17) GLUCONATE SODIUM\MAGNESIUM CHLORIDE\POTASSIUM CHLORIDE\SODIUM
ACETATE\SODIUM CHLORIDE (C)

(18) POTASSIUM PHOSPHATE (C)

(19) ACETYLSALICYLIC ACID (C)

(20) AMLODIPINE (C)

(21) ESCITALOPRAM (C)

(22) DONEPEZIL (C)

(23) MIRABEGRON (C)

(24) TAMSULOSIN (C)

(25) MEGESTROL (C)

(26) ATORVASTATIN (C)

(27) ESOMEPRAZOLE (C)

(28) CEFIXIME (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)

(29) AMLODIPINE BESILATE\VALSARTAN (C)

(30) MEROPENEM (T)

(31) PIPERACILLIN\TAZOBACTAM (T)

(32) CEFACLOR (T)

(33) METRONIDAZOLE (T)

(34) OXYCODONE HYDROCHLORIDE (T)

(35) PARACETAMOL (T)

(36) VANCOMYCIN (T)

(37) MEROPENEM (T)

(38) PETHIDINE (T)

(39) IBUPROFEN (T)

(40) CIPROFLOXACIN (T)
3143754
64
Female
CHINA
Febrile
infection
Grade 1
721
(1) PRALSETINIB (S)

(2) ASCORBIC ACID (C)


AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
Clinical
Study
Healthcare
Professional
(3) POTASSIUM CHLORIDE (C)

(4) PYRIDOXINE HYDROCHLORIDE (C)

(5) MOSAPRIDE CITRATE (C)

(6) MOXIFLOXACIN HYDROCHLORIDE (C)

(7) PANTOPRAZOLE (C)

(8) CEFTAZIDIME (C)

(9) LORATADINE (C)

(10) SPIRONOLACTONE (C)

(11) FUROSEMIDE (C)

(12) LOW MOLECULAR WEIGHT HEPARIN, CALCIUM SALT (C)

(13) PARACETAMOL (C)

(14) DIMETICONE (C)

(15) ALL OTHER THERAPEUTIC PRODUCTS (C)
3200448
51
Male
Nasopharyng
itis
Grade 1
1095
(1) PRALSETINIB (S)

(2) PARACETAMOL (T)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
KOREA,
REPUBLIC
OF
Clinical
Study
Healthcare
Professional

(3) AMOXICILLIN TRIHYDRATE\CLAVULANATE POTASSIUM (T)

(4) PARACETAMOL (T)
3207348
68
Male
ITALY
Clinical
Study
Healthcare
Professional
Pneumonia
Grade 2
28
(1) PRALSETINIB (S)

(2) CEFDITOREN PIVOXIL (T)

(3) OMEPRAZOLE (T)

(4) METHYLPREDNISOLONE (T)

(5) PARACETAMOL (T)
3211148
34
Female
CHINA
Non-
Interventional
Study/Progra
m
Non-
healthcare
professional
Pneumonia
Grade 1
(1) (1)
(1) PRALSETINIB (S)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
3214831
52
Male
FRANCE
Clinical
Study
Healthcare
Professional
Pseudomona
s infection
Grade 2
38
(1) PRALSETINIB (S)

(2) TESTOSTERONE ENANTHATE (C)

(3) OXYCODONE HYDROCHLORIDE (C)

(4) PREDNISOLONE METASULFOBENZOATE SODIUM (C)

(5) AMITRIPTYLINE HYDROCHLORIDE (C)

(6) POTASSIUM CHLORIDE (C)

(7) CALCIUM CARBONATE (C)

(8) METHADONE (C)

(9) HYDROCORTISONE (C)

(10) ENOXAPARIN SODIUM (C)

(11) ONDANSETRON (C)

(12) PIPERACILLIN SODIUM\TAZOBACTAM SODIUM (T)

(13) AMIKACIN (T)

(14) CIPROFLOXACIN (T)


AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
(15) CALCIUM CHLORIDE\MAGNESIUM CHLORIDE\MALIC ACID\POTASSIUM
CHLORIDE\SODIUM ACETATE\SODIUM CHLORIDE (T)
3220250
35
Male
UNITED
STATES OF
AMERICA
Clinical
Study
Healthcare
Professional
Postoperativ
e wound
infection


Grade 2
1460
(1) PRALSETINIB (S)

(2) ENOXAPARIN (C)

(3) KETOROLAC TROMETHAMINE (C)

(4) MAGNESIUM SULFATE (C)

(5) POTASSIUM CHLORIDE (C)

(6) PARACETAMOL (C)

(7) BUPROPION (C)

(8) HYDROMORPHONE (C)

(9) LAMOTRIGINE (C)

(10) LORAZEPAM (C)

(11) ONDANSETRON (C)

(12) OXYCODONE (C)

(13) MACROGOL 3350 (C)


AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
(14) PROCHLORPERAZINE (C)

(15) PROMETHAZINE (C)

(16) RIVAROXABAN (C)

(17) DOCUSATE SODIUM\SENNOSIDE A+B (C)

(18) SIMETICONE (C)

(19) BUPROPION (C)

(20) COLECALCIFEROL (C)

(21) LAMOTRIGINE (C)

(22) MENTHOL (C)

(23) RIVAROXABAN (C)

(24) ATENOLOL (C)

(25) AZITHROMYCIN (C)

(26) CEFALEXIN (C)

(27) PREDNISONE (C)


AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
(28) ASCORBIC ACID (C)

(29) DIPHENHYDRAMINE (C)

(30) TOZINAMERAN (C)

(31) DRONABINOL (C)

(32) GRAMICIDIN\NEOMYCIN SULFATE\POLYMYXIN B SULFATE (C)

(33) FENTANYL (C)

(34) POTASSIUM PHOSPHATE MONOBASIC\SODIUM PHOSPHATE DIBASIC\SODIUM
PHOSPHATE MONOBASIC (ANHYDROUS) (T)

(35) GLUCOSE (T)

(36) GABAPENTIN (T)

(37) LIDOCAINE (T)

(38) TIZANIDINE (T)

(39) CALCIUM CHLORIDE\POTASSIUM CHLORIDE\SODIUM LACTATE (T)

(40) EPINEPHRINE\LIDOCAINE HYDROCHLORIDE (T)

(41) PIPERACILLIN\TAZOBACTAM (T)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)

(42) SODIUM CHLORIDE (T)

(43) CIPROFLOXACIN (T)

(44) METRONIDAZOLE (T)
3255124
73
Female
FRANCE
Clinical
Study
Healthcare
Professional
Pneumonia


Grade 2
85
(1) PRALSETINIB (S)

(2) ALLOPURINOL (C)

(3) HYDROCHLOROTHIAZIDE\VALSARTAN (C)

(4) NEBIVOLOL (C)

(5) ACETYLSALICYLATE LYSINE (C)

(6) PARACETAMOL (C)

(7) LANSOPRAZOLE (C)

(8) PRAVASTATIN (C)

(9) BUDESONIDE (C)

(10) SALMETEROL XINAFOATE (C)

(11) MONTELUKAST SODIUM (C)


AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
(12) METFORMIN (C)

(13) LOPERAMIDE (C)

(14) LEVOFLOXACIN (C)

(15) DEXAMETHASONE\TOBRAMYCIN (C)

(16) HYALURONATE SODIUM (C)

(17) BRIMONIDINE TARTRATE\BRINZOLAMIDE (C)

(18) LATANOPROST (C)

(19) DEXAMETHASONE\OXYTETRACYCLINE (C)

(20) ATROPINE (C)

(21) CAFFEINE\PAPAVER SOMNIFERUM LATEX\PARACETAMOL (C)

(22) PARACETAMOL (C)

(23) TINZAPARIN SODIUM (C)

(24) AMOXICILLIN\CLAVULANATE POTASSIUM (T)

(25) HEPARIN (T)


AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
(26) TINZAPARIN SODIUM (T)

(27) SODIUM CHLORIDE (T)
3256323
59
Female
CHINA
Clinical
Study
Healthcare
Professional
Pneumonia
viral
Grade 2
904
(1) PRALSETINIB (S)

(2) ALLICIN (C)

(3) NADROPARIN CALCIUM (C)

(4) MAGNESIUM ISOGLYCYRRHIZINATE (C)

(5) INDOMETACIN (C)

(6) ACETYLCYSTEINE (C)

(7) ZOLEDRONIC ACID (C)

(8) ACETYLSALICYLATE LYSINE (C)

(9) DIAMMONIUM GLYCYRRHIZINATE (C)
3285099
64
Female
UNITED
STATES OF
AMERICA
Clinical
Study
COVID-19
Grade 1
870
(1) PRALSETINIB (S)

(2) ASCORBIC ACID (C)

(3) RANITIDINE HYDROCHLORIDE (C)

(4) POTASSIUM CHLORIDE (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
Healthcare
Professional
3296579
48
Female
CHINA
Clinical
Study
Healthcare
Professional
Pneumonia
Grade 2
1095
(1) PRALSETINIB (S)

(2) CALCIUM CARBONATE\COLECALCIFEROL (C)

(3) ALBUMIN HUMAN (C)

(4) ESOMEPRAZOLE MAGNESIUM (C)

(5) LATAMOXEF SODIUM (T)

(6) IPRATROPIUM BROMIDE\SALBUTAMOL SULFATE (T)

(7) ACETYLCYSTEINE (T)

(8) LEVOFLOXACIN (T)

(9) BUDESONIDE (T)

(10) METHYLPREDNISOLONE (T)

(11) ACETYLCYSTEINE (T)

(12) METHYLPREDNISOLONE (T)
3301305
30
Female
Pneumonia
Grade 2
1094
(1) PRALSETINIB (S)

(2) LEVOTHYROXINE SODIUM (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
CHINA
Clinical
Study
Healthcare
Professional

(3) AMOXICILLIN (C)

(4) CEFRADINE (T)

(5) FRITILLARIA SPP. BULB (T)

(6) LORATADINE (T)

(7) CEFOPERAZONE SODIUM\SULBACTAM SODIUM (T)

(8) RIBAVIRIN (T)

(9) BUDESONIDE (T)

(10) ALBUMIN HUMAN (T)
3383099
53
Male
FRANCE
Clinical
Study
Healthcare
Professional
Pneumocysti
s jirovecii
pneumonia
Grade 2
272
(1) PRALSETINIB (S)

(2) TESTOSTERONE ENANTHATE (C)

(3) PREDNISOLONE (C)

(4) AMITRIPTYLINE HYDROCHLORIDE (C)

(5) POTASSIUM CHLORIDE (C)

(6) CALCIUM CARBONATE (C)


AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
(7) METHADONE (C)

(8) HYDROCORTISONE (C)

(9) SULFAMETHOXAZOLE\TRIMETHOPRIM (T)
3430268
77
Male
ROMANIA
Clinical
Study
Healthcare
Professional
COVID-19
Grade 1
4
(1) PRALSETINIB (S)

(2) DEXAMETHASONE (C)

(3) KETOPROFEN (C)

(4) METAMIZOLE (C)

(5) OXYGEN (T)
3479467
38
Male
GERMANY
Clinical
Study
Non-
healthcare
professional
Influenza
Grade 2
1825
(1) PRALSETINIB (S)
3484843
47
Male
ITALY
Clinical
Pneumonia
Grade 2
90
(1) PRALSETINIB (S)

(2) PIPERACILLIN SODIUM\TAZOBACTAM SODIUM (T)

(3) PREDNISONE (T)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
Study
Healthcare
Professional

(4) PARACETAMOL (T)

(5) MEROPENEM (T)

(6) ENOXAPARIN SODIUM (T)
3491936
49
Female
CHINA
Clinical
Study
Healthcare
Professional
Pneumonia
Grade 2
1460
(1) PRALSETINIB (S)

(2) LEVOFLOXACIN (S)

(3) SODIUM CHLORIDE (S)

(4) CEFOPERAZONE SODIUM (S)

(5) SULBACTAM SODIUM (S)

(6) CALCIUM CARBONATE (C)

(7) COLECALCIFEROL (C)
3498224
65
Male
KOREA,
REPUBLIC
OF
Clinical
Study
Pneumonia
Grade 2
1825
(1) PRALSETINIB (S)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
Healthcare
Professional
3509447
81
Female
JAPAN
Clinical
Study
Healthcare
Professional
Pneumonia
Grade 2
11
(1) PRALSETINIB (S)

(2) ATORVASTATIN (C)

(3) SITAGLIPTIN PHOSPHATE (C)

(4) BAZEDOXIFENE ACETATE (C)

(5) NIFEDIPINE (C)

(6) PREGABALIN (C)

(7) ELOBIXIBAT (C)

(8) SENNOSIDE A+B (C)

(9) FLUTICASONE FUROATE (C)

(10) LEVOFLOXACIN (T)
3520638
74
Male
ITALY
Clinical
Study
Bronchitis
Grade 2
189
(1) PRALSETINIB (S)

(2) LAMIVUDINE (C)

(3) DENOSUMAB (C)

(4) CALCIUM CARBONATE (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
Healthcare
Professional

(5) COLECALCIFEROL (C)

(6) METHYLPREDNISOLONE (T)

(7) CLARITHROMYCIN (T)

(8) CEFTRIAXONE SODIUM (T)

(9) CEFIXIME (T)

(10) PREDNISONE (T)

(11) BECLOMETASONE DIPROPIONATE (T)

(12) CEFEPIME (T)
3528114
26
Female
TURKIYE
Clinical
Study
Healthcare
Professional
COVID-19
Grade 2
8
(1) PRALSETINIB (S)

(2) TRAMADOL HYDROCHLORIDE (C)

(3) ONDANSETRON HYDROCHLORIDE (C)

(4) PARACETAMOL (C)

(5) PANTOPRAZOLE SODIUM SESQUIHYDRATE (C)
3528460
60
Male
Gastroenteriti
s
Grade 2
1095
(1) PRALSETINIB (S)

(2) PANTOPRAZOLE SODIUM SESQUIHYDRATE (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
ITALY
Clinical
Study
Non-
healthcare
professional

(3) ONDANSETRON (C)

(4) FENTANYL (C)

(5) PREGABALIN (C)

(6) MORPHINE SULFATE PENTAHYDRATE (C)

(7) CEFTRIAXONE (T)

(8) FENTANYL (T)

(9) PREGABALIN (T)
3528527
60
Male
ITALY
Clinical
Study
Non-
healthcare
professional
Gastroenteriti
s
Grade 2
1095
(1) PRALSETINIB (S)

(2) ALL OTHER THERAPEUTIC PRODUCTS (T)

(3) CIPROFLOXACIN (T)

(4) PROBIOTICS NOS (T)
2934155
55
Male
UNITED
STATES OF
Sepsis

Pneumonia
Grade 4
884

884
(1) PRALSETINIB (S)

(2) IPRATROPIUM BROMIDE\SALBUTAMOL SULFATE (C)

(3) NAPROXEN (C)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
AMERICA
Clinical
Study
Healthcare
Professional

Grade 2
2802164
87
Male
UNITED
STATES OF
AMERICA
Clinical
Study
Non-
healthcare
professional
Sepsis

Urinary tract
infection
Grade 5

Grade 2
10

10
(1) PRALSETINIB (S)

(2) AMLODIPINE (C)

(3) LISINOPRIL (C)

(4) SILODOSIN (C)

(5) DUTASTERIDE (C)

(6) LEVOTHYROXINE (C)

(7) FINASTERIDE (C)

(8) FAMOTIDINE (C)

(9) CEFEPIME HYDROCHLORIDE (T)

(10) ACICLOVIR (T)

(11) HALOPERIDOL (T)

(12) VANCOMYCIN (T)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)

(13) MORPHINE (T)
2796030
59
Male
UNITED
STATES OF
AMERICA
Clinical
Study
Healthcare
Professional
Sepsis

Bacteraemia
Grade 4

Grade 2
7

10
(1) PRALSETINIB (S)

(2) CALCIUM CARBONATE (C)

(3) OXYGEN (C)

(4) LEVOTHYROXINE (C)

(5) RANITIDINE (C)

(6) ROSUVASTATIN (C)

(7) LACOSAMIDE (C)

(8) LEVETIRACETAM (C)

(9) LORAZEPAM (C)

(10) ONDANSETRON (C)

(11) PANTOPRAZOLE (C)

(12) MACROGOL (C)

(13) CEFEPIME HYDROCHLORIDE (T)

AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)

(14) VANCOMYCIN HYDROCHLORIDE (T)
2797521
66
Male
UNITED
STATES OF
AMERICA
Clinical
Study
Healthcare
Professional
Escherichia
sepsis

Escherichia
bacteraemia
Grade 4

Grade 2
212

212
(1) PRALSETINIB (S)

(2) MORPHINE SULFATE (C)

(3) MACROGOL 3350 (C)

(4) SENNOSIDE A+B (C)

(5) SALBUTAMOL (C)

(6) SODIUM CHLORIDE (C)

(7) SERTRALINE HYDROCHLORIDE (C)

(8) PARACETAMOL (C)

(9) ONDANSETRON (C)

(10) MEROPENEM (T)

(11) SALBUTAMOL (T)

(12) SALBUTAMOL (T)

(13) ACETYLSALICYLIC ACID (T)


AER
Number
Age in
Years
Sex
Primary
Source
Country
Primary
Source
Reporter
Type
Event
Preferred
Term of
Interest*
Severity
Grade
Time to
Onset (in
days)
Drug Type (All)
(14) MUPIROCIN (T)

(15) CEFTRIAXONE (T)


80
Drug Safety Report No: 1132062
Appendix 9
Listings of Non-serious Cases Reporting Events of
Infections from Safety Database (N=66)

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to onset (in days)
Drug Type (All)
2712220
Not reported
Male
UNITED STATES OF AMERICA
Spontaneous
Non-healthcare professional
Herpes zoster
NR
Not reported
(1) PRALSETINIB (S)

(2) MACROGOL 3350 (T)
2760057
Not reported
Male
UNITED STATES OF AMERICA
Spontaneous
Non-healthcare professional
Herpes zoster
NR
Not reported
(1) PRALSETINIB (S)

(2) AMLODIPINE (C)

(3) ALPRAZOLAM (C)
2786698
72
Male
UNITED STATES OF AMERICA
Spontaneous
Non-healthcare professional
Bacterial infection
NR
(1) (1) 104
(1) PRALSETINIB (S)
2809616
84
Female
UNITED STATES OF AMERICA
Spontaneous
Non-healthcare professional
Oral fungal infection

Urinary tract infection
NR
(1) (1) 120

(1) (2) 120
(1) PRALSETINIB (S)
2845240
Not reported
Female
UNITED STATES OF AMERICA
Spontaneous
Non-healthcare professional
Urinary tract infection
NR
Not reported
(1) PRALSETINIB (S)

(2) LEVOFLOXACIN (S)

(3) HYDROCODONE
BITARTRATE\PARACETAMOL (T)
2850007
84
Female
UNITED STATES OF AMERICA
Infection
NR
(1) (1) 0
(1) PRALSETINIB (S)

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to onset (in days)
Drug Type (All)
Spontaneous
Non-healthcare professional
2851557
Not reported
Male
UNITED STATES OF AMERICA
Spontaneous
Non-healthcare professional
Nasopharyngitis
NR
Not reported
(1) PRALSETINIB (S)
2852909
59
Male
KOREA, REPUBLIC OF
Non-Interventional Study/Program
Non-healthcare professional
Oral candidiasis
NR
(1) (1) 14
(1) PRALSETINIB (S)
2858278
Not reported
Female
UNITED STATES OF AMERICA
Spontaneous
Non-healthcare professional
Oral fungal infection
NR
Not reported
(1) PRALSETINIB (S)
2881194
66
Female
CHINA
Spontaneous
Healthcare professional
 Cystitis
NR
(1) (4) 13
(1) PRALSETINIB (S)

(2) CAMRELIZUMAB (C)

(3) NITROFURANTOIN (T)

(4) ALOE VERA (T)
2894543
65
Male
CHINA
Spontaneous
Non-healthcare professional
Abscess limb


NR
Not reported
(1) PRALSETINIB (S)

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to onset (in days)
Drug Type (All)
2907361
34
Female
CHINA
Spontaneous
Non-healthcare professional
Laryngopharyngitis


NR
Not reported
(1) PRALSETINIB (S)
2910947
77
Female
CHINA
Spontaneous
Non-healthcare professional
Paronychia


NR
Not reported
(1) PRALSETINIB (S)
2949447
48
Male
CHINA
Non-Interventional Study/Program
Non-healthcare professional
Fungal infection

Fungal skin infection
NR
(1) (3) 83

(1) (9) 120
(1) PRALSETINIB (S)

(2) LEUCOGEN (T)
2965786
47
Male
CHINA
Non-Interventional Study/Program
Non-healthcare professional
Paronychia


NR
(1) (1) 210
(1) PRALSETINIB (S)
2989008
51
Male
TURKIYE
Non-Interventional Study/Program
Healthcare professional
COVID-19
NR
(1) (2) 106
(1) PRALSETINIB (S)
2994720
Not reported
Male
CHINA
Tinea infection
NR
(1) (1) 124
(1) PRALSETINIB (S)

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to onset (in days)
Drug Type (All)
Non-Interventional Study/Program
Non-healthcare professional
3001092
51
Female
KOREA, REPUBLIC OF
Non-Interventional Study/Program
Healthcare professional
Coronavirus infection
NR
(1) (2) 498
(1) PRALSETINIB (S)
3080808
67
Male
CHINA
Non-Interventional Study/Program
Non-healthcare professional
Paronychia
NR
(1) (2) 30
(1) PRALSETINIB (S)
3090360
55
Male
UNITED STATES OF AMERICA
Non-Interventional Study/Program
Non-healthcare professional
Nasopharyngitis
NR
Not reported
(1) PRALSETINIB (S)
3100273
63
Female
CHINA
Non-Interventional Study/Program
Non-healthcare professional
Urinary tract infection


NR
(1) (3) 330
(1) PRALSETINIB (S)
3103964
56
Female
CHINA
Non-Interventional Study/Program
Non-healthcare professional
Paronychia
NR
Not reported
(1) PRALSETINIB (S)
3116502
Not reported
Herpes zoster
NR
Not reported
(1) PRALSETINIB (S)

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to onset (in days)
Drug Type (All)
Not reported
CHINA
Non-Interventional Study/Program
Non-healthcare professional
3122710
62
Male
CHINA
Non-Interventional Study/Program
Non-healthcare professional
Urinary tract infection


NR
Not reported
(1) PRALSETINIB (S)
3122711
52
Female
CHINA
Non-Interventional Study/Program
Non-healthcare professional
Urinary tract infection
NR
(1) (1) 224
(1) PRALSETINIB (S)
3147568
41
Female
CHINA
Non-Interventional Study/Program
Non-healthcare professional
Urinary tract infection
NR
(1) (11) 145
(1) PRALSETINIB (S)
3169172
42
Female
ITALY
Non-Interventional Study/Program
Healthcare professional
COVID-19
NR
(1) (1) 365
(1) PRALSETINIB (S)

(2) OTHER MONOCLONAL ANTIBODIES
AND ANTIBODY DRUG CONJUGATES
(T)
3202186
85
Male
UNITED STATES OF AMERICA
Non-Interventional Study/Program
Non-healthcare professional
Infection
NR
Not reported
(1) PRALSETINIB (S)

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to onset (in days)
Drug Type (All)
3215171
64
Female
CHINA
Non-Interventional Study/Program
Healthcare professional
Urinary tract infection
NR
(1) (4) 60
(1) PRALSETINIB (S)
3218767
Not reported
Female
ISRAEL
Spontaneous
Non-healthcare professional
Genital herpes
NR
Not reported
(1) PRALSETINIB (S)
3222453
22
Female
CHINA
Non-Interventional Study/Program
Healthcare professional
Paronychia
NR
(1) (1) 204
(1) PRALSETINIB (S)
3225065
85
Male
UNITED STATES OF AMERICA
Non-Interventional Study/Program
Non-healthcare professional
Tongue fungal infection
NR
Not reported
(1) PRALSETINIB (S)
3229307
80
Female
UNITED STATES OF AMERICA
Non-Interventional Study/Program
Non-healthcare professional
Nasopharyngitis
NR
Not reported
(1) PRALSETINIB (S)
3230719
80
Male
UNITED STATES OF AMERICA
COVID-19
NR
Not reported
(1) PRALSETINIB (S)

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to onset (in days)
Drug Type (All)
Non-Interventional Study/Program
Non-healthcare professional
3264550
48
Male
CHINA
Spontaneous
Non-healthcare professional
COVID-19
NR
(1) (1) 10
(1) PRALSETINIB (S)
3268157
65
Female
GERMANY
Spontaneous
Healthcare professional
Urinary tract infection


NR
Not reported
(1) PRALSETINIB (S)

(2) CIPROFLOXACIN (T)
3276717
63
Female
UNITED STATES OF AMERICA
Non-Interventional Study/Program
Non-healthcare professional
COVID-19

Sinusitis
NR
Not reported
(1) PRALSETINIB (S)
3291127
Not reported
Female
ISRAEL
Non-Interventional Study/Program
Non-healthcare professional
Sinusitis fungal
NR
Not reported
(1) PRALSETINIB (S)
3298850
Not reported
Male
CHINA
Non-Interventional Study/Program
Non-healthcare professional
COVID-19


NR
(1) (1) 349
(1) PRALSETINIB (S)
3300832
Not reported
COVID-19

(1) (1) 349
(1) PRALSETINIB (S)

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to onset (in days)
Drug Type (All)
Not reported
CHINA
Non-Interventional Study/Program
Non-healthcare professional

NR
3303724
Not reported
Male
CHINA
Non-Interventional Study/Program
Non-healthcare professional
COVID-19
NR
Not reported
(1) PRALSETINIB (S)
3310244
Not reported
Male
CHINA
Non-Interventional Study/Program
Non-healthcare professional
Herpes virus infection
NR
(1) (1) 321
(1) PRALSETINIB (S)
3330176
52
Female
UNITED STATES OF AMERICA
Non-Interventional Study/Program
Non-healthcare professional
Nasopharyngitis
NR
Not reported
(1) PRALSETINIB (S)
3334423
Not reported
Female
FRANCE
Spontaneous
Non-healthcare professional
Infection
NR
Not reported
(1) PRALSETINIB (S)
3340335
Not reported
Female
CHINA
Non-Interventional Study/Program
Non-healthcare professional
Paronychia


NR
Not reported
(1) PRALSETINIB (S)

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to onset (in days)
Drug Type (All)
3356437
Not reported
Female
CHINA
Non-Interventional Study/Program
Non-healthcare professional
Pulpitis dental
NR
(1) (1) 365
(1) PRALSETINIB (S)
3360987
83
Female
SPAIN
Non-Interventional Study/Program
Healthcare professional
Respiratory tract infection
NR
Not reported
(1) PRALSETINIB (S)
3366826
61
Female
CHINA
Non-Interventional Study/Program
Non-healthcare professional
Oral herpes
NR
(1) (1) 60
(1) PRALSETINIB (S)
3382569
Not reported
Female
UNITED STATES OF AMERICA
Spontaneous
Non-healthcare professional
Fungal foot infection


NR
Not reported
(1) PRALSETINIB (S)
3386201
Not reported
Not reported
CHINA
Non-Interventional Study/Program
Non-healthcare professional
Laryngopharyngitis


NR
(1) (1) 94
(1) PRALSETINIB (S)
3387498
59
Female
CHINA
Urinary tract infection
NR
(1) (1) 180
(1) PRALSETINIB (S)

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to onset (in days)
Drug Type (All)
Non-Interventional Study/Program
Non-healthcare professional
3399349
68
Male
UNITED STATES OF AMERICA
Non-Interventional Study/Program
Non-healthcare professional
Cellulitis
NR
Not reported
(1) PRALSETINIB (S)
3410099
Not reported
Male
CHINA
Non-Interventional Study/Program
Non-healthcare professional
Paronychia


NR
(1) (2) 211
(1) PRALSETINIB (S)
3416674
Not reported
Male
CHINA
Non-Interventional Study/Program
Non-healthcare professional
Herpes zoster
NR
(1) (1) 594
(1) PRALSETINIB (S)
3429265
75
Female
UNITED STATES OF AMERICA
Non-Interventional Study/Program
Non-healthcare professional
COVID-19


NR
Not reported
(1) PRALSETINIB (S)
3438102
62
Male
UNITED STATES OF AMERICA
Literature Spontaneous
Non-healthcare professional
Pulmonary tuberculosis
NR
Not reported
(1) PRALSETINIB (S)
3457463
Not reported
Bacterial infection
NR
Not reported
(1) PRALSETINIB (S)

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to onset (in days)
Drug Type (All)
Not reported
UNITED STATES OF AMERICA
Literature Spontaneous
Non-healthcare professional
3471116
46
Male
UNITED STATES OF AMERICA
Non-Interventional Study/Program
Non-healthcare professional
Pneumonia
NR
Not reported
(1) PRALSETINIB (S)
3477159
70
Female
UNITED STATES OF AMERICA
Non-Interventional Study/Program
Non-healthcare professional
Laryngitis
NR
Not reported
(1) PRALSETINIB (S)
3479890
73
Male
CHINA
Non-Interventional Study/Program
Non-healthcare professional
Herpes zoster
NR
Not reported
(1) PRALSETINIB (S)
3489984
73
Female
UNITED STATES OF AMERICA
Non-Interventional Study/Program
Non-healthcare professional
Nasopharyngitis
NR
Not reported
(1) PRALSETINIB (S)
3500721
59
Male
ITALY
Non-Interventional Study/Program
Non-healthcare professional
Pneumonia
NR
Not reported
(1) PRALSETINIB (S)

AER No
Age in Years
Sex
Country
Primary Source
Reporter Type
Event Preferred Term of
Interest*
Severity Grade
Time to onset (in days)
Drug Type (All)
3528080
Not reported
Female
CHINA
Non-Interventional Study/Program
Healthcare professional
Abscess
NR
Not reported
(1) PRALSETINIB (S)

(2) OSIMERTINIB (S)
3551014
57
Female
UNITED STATES OF AMERICA
Non-Interventional Study/Program
Non-healthcare professional
Ear infection
NR
Not reported
(1) PRALSETINIB (S)
10000018795
Not reported
Not reported
FRANCE
Spontaneous
Healthcare professional
Infection
NR
Not reported
(1) PRALSETINIB (S)
10000034956
Not reported
Not reported
UNITED STATES OF AMERICA
Spontaneous
Non-healthcare professional
COVID-19
NR
Not reported
(1) PRALSETINIB (S)


```